U.S. patent application number 10/532618 was filed with the patent office on 2006-06-29 for cosmetic and pharmaceutical foam.
This patent application is currently assigned to Foamix Ltd.. Invention is credited to Meir Eini, Doron Friedman, Dov Tamarkin.
Application Number | 20060140984 10/532618 |
Document ID | / |
Family ID | 32178937 |
Filed Date | 2006-06-29 |
United States Patent
Application |
20060140984 |
Kind Code |
A1 |
Tamarkin; Dov ; et
al. |
June 29, 2006 |
Cosmetic and pharmaceutical foam
Abstract
The invention relates to an alcohol-free cosmetic or
pharmaceutical foam carrier comprising water, a hydrophobic
solvent, a foam adjuvant agent, a surface-active agent and a water
gelling agent. The cosmetic or pharmaceutical foam carrier does not
contain aliphatic alcohols, making it non-irritating and
non-drying. The alcohol-free foam carrier is suitable for inclusion
of both water-soluble and oil soluble pharmaceutical and cosmetic
agents.
Inventors: |
Tamarkin; Dov; (Maccabim,
IL) ; Friedman; Doron; (Karmei Yosef, IL) ;
Eini; Meir; (Ness Ziona, IL) |
Correspondence
Address: |
WILMER CUTLER PICKERING HALE AND DORR LLP
60 STATE STREET
BOSTON
MA
02109
US
|
Assignee: |
Foamix Ltd.
2 Hashaked Street
Ness Ziona
IL
74104
|
Family ID: |
32178937 |
Appl. No.: |
10/532618 |
Filed: |
October 24, 2003 |
PCT Filed: |
October 24, 2003 |
PCT NO: |
PCT/IB03/05527 |
371 Date: |
December 22, 2005 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
60429546 |
Nov 29, 2002 |
|
|
|
Current U.S.
Class: |
424/400 |
Current CPC
Class: |
A61P 33/00 20180101;
A61K 8/60 20130101; A61P 17/02 20180101; A61K 47/26 20130101; A61K
9/122 20130101; A61K 47/46 20130101; A61K 9/0034 20130101; A61K
47/06 20130101; A61Q 19/04 20130101; A61K 9/0007 20130101; A61P
1/00 20180101; A61K 9/12 20130101; A61K 31/351 20130101; A61K
38/212 20130101; A61P 37/06 20180101; A61K 31/7048 20130101; A61P
5/00 20180101; A61P 31/10 20180101; A61K 47/34 20130101; A61Q 7/02
20130101; A61P 31/04 20180101; A61K 31/535 20130101; A61K 31/522
20130101; A61P 17/00 20180101; A61Q 17/04 20130101; A61Q 17/02
20130101; A61K 8/046 20130101; A61K 47/10 20130101; A61K 9/107
20130101; A61P 31/12 20180101; A61K 31/4174 20130101; A61K 9/0014
20130101; A01N 25/16 20130101; A61K 47/14 20130101; A61P 17/16
20180101; A61K 47/38 20130101; A61K 31/137 20130101; A61P 29/00
20180101; A61K 2800/75 20130101; A61P 37/08 20180101; A61Q 7/00
20130101; A61Q 19/02 20130101; A61K 31/567 20130101; A61K 47/20
20130101; A61P 23/00 20180101; A61K 38/12 20130101; A61P 35/00
20180101; A61K 31/7036 20130101; A61P 17/14 20180101; A61K 31/573
20130101; A61K 31/4164 20130101 |
Class at
Publication: |
424/400 |
International
Class: |
A61K 9/00 20060101
A61K009/00 |
Foreign Application Data
Date |
Code |
Application Number |
Oct 25, 2002 |
IL |
152486 |
Claims
1. An alcohol-free foamable pharmaceutical or cosmetic carrier,
comprising: (a) a foamable composition comprising: about 2-75% by
weight of composition of a liquid, non-volatile hydrophobic
solvent; about 80-98% by weight of composition of water; about 0.1%
to 5% by weight of composition of a foam adjuvant agent selected
from the group consisting of fatty alcohols, fatty acids,
hydroxyl-substituted fatty alcohols, hydroxyl-substituted fatty
acids, and fatty acids and fatty alcohols including at least one
double bond in its carbon atom chain; about 0.1% to 5% by weight of
composition of a surface-active agent; and about 0.1% to 5% by
weight of composition of a water gelling agent and (b) a liquefied
or compressed gas propellant in a container, which upon release
provides a breakable foam suitable for topical or muscosal
administration.
2. The foamable carrier of claim 1, wherein the hydrophobic solvent
comprises about 5-10% by weight of composition.
3. The foamable carrier of claim 1, wherein the hydrophobic solvent
comprises about 10-20% by weight of composition.
4. The foamable carrier of claim 1, wherein the hydrophobic solvent
comprises about 20-75% by weight of composition.
5. The foamable carrier of claim 1, wherein the hydrophobic solvent
comprises a mixture of mineral oil and an emollient in a ratio
between 2:8 and 8:2 on a weight basis.
6. The foamable carrier of claim 1, wherein at least 2% of the
foamable composition is a silicone oil.
7. (canceled)
8. The foamable carrier of claim 1, wherein the surface-active
agent is a mixture of a non ionic surfactant and an anionic
surfactant in a 20:1 to 1:1 ratio.
9. The foamable carrier of claim 1, wherein the surface-active
agent is a mixture of a non-ionic surfactant and an ionic
surfactant in a 100:1 to 6:1 ratio.
10. The foamable carrier of claim 1, wherein the surface-active
agent consists essentially of one or more non-ionic
surfactants.
11. The foamable carrier of claim 1, wherein the surface-active
agent has HLB value of more than 9.
12. The foamable carrier of claim 10, wherein the non-ionic
surfactant comprises a sucrose ester.
13. The foamable carrier of claim 1, wherein the hydrophobic
solvent is selected from the group comprising vegetable oils,
marine oils, mineral oils, emollients, silicone oils, plant-derived
therapeutic oils and mixture thereof.
14. The foamable carrier of claim 1, wherein the combined amount of
foam adjuvant agent, surface-active agent and water gelling agent
is less than about 8% (w/w).
15. The foamable carrier of claim 1, wherein the combined amount of
foam adjuvant agent, surface-active agent and water gelling agent
is less than about 5% (w/w) of the foamable composition.
16. A pharmaceutical or cosmetic composition, comprising: (a) a
foamable composition comprising: about 2-75% by weight of
composition of a liquid, non-volatile hydrophobic solvent; about
80-98% by weight of composition of water; about 0.1% to 5% by
weight of composition of a foam adjuvant agent selected from the
group consisting of fatty alcohols, fatty acids,
hydroxyl-substituted fatty alcohols, hydroxyl-substituted fatty
acids, and fatty acids and fatty alcohols including at least one
double bond in its carbon atom chain; about 0.1% to 5% by weight of
composition surface-active agent; and about 0.1% to 5% by weight of
composition water gelling agent; (b) a therapeutically effective
amount of an active agent; and (c) a liquefied or compressed gas
propellant in a container, which upon release provides a breakable
foam suitable for topical or muscasol administration.
17. The pharmaceutical or cosmetic composition of claim 16, wherein
the hydrophobic solvent comprises about 5-10% by weight of
composition.
18. The pharmaceutical or cosmetic composition of claim 16, wherein
the hydrophobic solvent comprises about 10-20% by weight of
composition.
19. The pharmaceutical or cosmetic composition of claim 16, wherein
the hydrophobic solvent comprises about 20-75% by weight of
composition.
20. (canceled)
21. The pharmaceutical or cosmetic composition of claim 16, wherein
the active agent is a cosmetically effective agent.
22. The pharmaceutical or cosmetic composition of claim 16, wherein
the hydrophobic solvent is selected from the group comprising
vegetable oils, marine oils, mineral oils, emollient, silicone
oils, plant-derived therapeutic oils and mixture thereof at any
proportion.
23. The pharmaceutical or cosmetic composition of claim 16, further
comprising excipients selected from the group consisting of
antioxidants, humectants, flavoring, colorant and odorant
agents.
24. The pharmaceutical or cosmetic composition of claim 16, wherein
the hydrophobic solvent comprises a mixture of mineral oil and an
emollient in a ratio between 2:8 and 8:2 on a weight basis.
25. The pharmaceutical or cosmetic composition of claim 16, wherein
at least 2% of the composition is a silicone oil.
26. The pharmaceutical or cosmetic composition of claim 16, wherein
the surface-active agent is a mixture of a non ionic surfactant and
an anionic surfactant in a 20:1 to 1:1 ratio.
27. The pharmaceutical or cosmetic composition of claim 16, wherein
the surface-active agent consists essentially of one or more
non-ionic surfactants.
28. The pharmaceutical or cosmetic composition of claim 16, wherein
the surface-active agent is a mixture of a non-ionic surfactant and
an ionic surfactant in a 100:1 to 6:1 ratio.
29. The pharmaceutical or cosmetic composition of claim 16, wherein
the combined amount of foam adjuvant agent, surface active agent
and water gelling agent is less than about 8% (w/w).
30. The composition of claim 16, further comprising an effective
concentration of a penetration enhancer.
31. The pharmaceutical or cosmetic composition of claim 16, wherein
the combined amount of foam adjuvant agent, surface active agent
and water gelling agent is less than about 5% (w/w).
32. The pharmaceutical or cosmetic composition of claim 16, wherein
the active agent is selected for the treatment of a disease, the
etiology of which is bacterial, fungal, viral, parasitic,
inflammatory, autoimmune, allergic, hormonal, malignant and
combinations thereof.
33. (canceled)
34. The composition of claim 16, wherein the active agent is
selected for the treatment of a disorder of the skin, mucosal
membrane, vagina and rectum.
35. The composition of claim 16, wherein the active agent is
selected for the treatment of a disorder, selected from the group
of dermatosis, dermatitis, bacterial Infections, fungal Infections,
parasitic infections, viral infections, disorders of hair follicles
and sebaceous glands, acne, rosacea, scaling papular diseases,
benign tumors, malignant tumors, reactions to sunlight, bullous
diseases, pigmentation disorders, disorders of cornification,
pressure sores, disorders of sweating, inflammatory reactions,
xerosis, ichthyosis, allergy, burn, wound, cut, and
non-dermatological disorders, which respond to transdermal delivery
of said drug.
36. (canceled)
37. The composition of claim 16, wherein the active agent is
selected from the group consisting of antibacterial agents,
antifungal agents, antiviral agents, insecticides, insect
repellents, anti-inflammatory or antiallergic agents, anticancer
agents, photodynamic therapy agents, local anesthetics,
nonsteroidal anti-inflammatory drugs (NSAIDs), and an herbal
extract, a radical scavenger, and an anti-acne cream.
38. (canceled)
39. (canceled)
40. (canceled)
41. (canceled)
42. (canceled)
43. (canceled)
44. (canceled)
45. (canceled)
46. (canceled)
47. The composition of claim 21, wherein the active agent is
selected from the group consisting of retinoids. anti-wrinkle
agents, skin whitening agents. self-tanning agents, herbal
extracts, radical scavengers, anti-acne agents, and figure forming
agents.
48. (canceled)
49. (canceled)
50. The composition of claim 16, wherein said active agent is
selected from the group comprising sulfur-containing amino acids,
thiol compounds, alpha hydroxy acids, lactic acid and its
derivatives and salts, glycolic acid and its derivatives and salts,
beta-hydroxy acids, salicylic acid and salicylic acid salts and
derivatives, phytic acid, lipoic acid, lysophosphatidic acid, skin
peel agents, phenol, resorcinol, vitamin B3 compounds, niacinamide,
nicotinic acid and nicotinic acid salts and esters, tocopheryl
nicotinate, nicotinyl amino acids, nicotinyl alcohol esters of
carboxylic acids, nicotinic acid N-oxide and niacinamide N-oxide,
retinoids, retinol, retinal, retinoic acid, retinyl acetate,
retinyl palmitate, retinyl ascorbate, caffeine, theophiline,
pentoxyphilline, dihydroxy acetone kojic acid, arbutin, nicotinic
acid and its precursors, salts and derivatives, arbutin, ascorbic
acid and salts and derivatives thereof.
51. (canceled)
52. (canceled)
53. (canceled)
54. (canceled)
55. (canceled)
56. (canceled)
57. The composition of claim 21, wherein the active agent is an
agent that influences hair growth, a hair growth stimulation agent,
or a hair growth inhibiting agent.
58. (canceled)
59. (canceled)
60. The composition of claim 16, further comprising a sunscreen
agent.
61. (canceled)
62. The composition of claim 16, wherein the active agent is a
combination of a skin whitening agent and a sunscreen agent.
63. The composition of claim 16, wherein the active agent is a
combination of a skin whitening agent and an inorganic sunscreen
agent.
64. The composition of claim 16 wherein the active agent is
intended for transdermal delivery.
65. The composition of claim 16, further comprising a
decontaminating agent selected from the group comprising an
oxidizing agent, iodine and iodine compounds, chlorohexidine,
bleaching agents and surface-active agents.
66. A method of treating, alleviating or preventing a
dermatological disorder, comprising: administering topically to a
subject having said dermatological disorder a therapeutically
effective amount of a breakable foam composition comprising: (a) a
foamable composition comprising: about 2-75% by weight of
composition of a liquid, non-volatile hydrophobic solvent; about
80-98% by weight of composition of water; about 0.1% to 5% by
weight of composition of a foam adjuvant agent selected from the
group consisting of fatty alcohols, fatty acids,
hydroxyl-substituted fatty alcohols, hydroxyl-substituted fatty
acids, and fatty acids and fatty alcohols including at least one
double bond in its carbon atom chain; about 0.1% to 5% by weight of
composition of a surface-active agent; and about 0.1% to 5% by
weight of composition of a water gelling agent. (b) at least one
active agent, which is intended to prevent, alleviate or cure said
disorder; and (c) a liquefied or compressed gas propellant.
67. The method of claim 66, wherein at least 2% of the composition
is a silicone oil.
68. The method of claim 66, wherein the hydrophobic solvent
comprises a mixture of mineral oil and an emollient in a ratio
between 2:8 and 8:2 on a weight basis.
69. The method of claim 66, wherein the surface-active agent is
selected from the groups of non-ionic surfactants, cationic
surfactants, amphoteric and zwitterionic surfactants.
70. The method of claim 66, wherein the surface-active agent is a
mixture of a non-ionic surfactant and an anionic surfactant in a
1:1 to 20:1 ratio.
71. The method of claim 66, wherein the surface-active agent is
non-ionic.
72. The method of claim 66, wherein the surface-active agent has
HLB value of more than 9.
73. The method of claim 66, wherein the non-ionic surfactant
comprises a sucrose ester.
74. The method of claim 66, wherein the active agent is intended
for the treatment of a disease, the etiology of which is bacterial,
fungal, viral, parasitic, inflammatory, autoimmune, allergic,
hormonal, malignant and combinations thereof.
75. The method of claim 66, wherein the active agent is selected
from the group comprising antibacterial, antifungal,
anti-inflammatory, antiallergic, nonsteroidal anti-inflammatory,
retinoid, alpha hydroxy acid, beta hydroxy acid, keratolytic,
antiproliferative, anticancer and anti-pigmentation drugs.
76. The method of claim 66, wherein the active agent is selected
from the group comprising insecticides, insect repellents, and
figure forming agents.
77. The method of claim 66, wherein said active agent is applied
topically to an affected area.
78. The method of claim 66, wherein said dermatological disorder is
a disorder selected from the group, consisting of dermatosis,
dermatitis, bacterial Infections, fungal Infections, parasitic
infections, viral infections, disorders of hair follicles and
sebaceous glands, scaling papular diseases, benign tumors,
malignant tumors, reactions to sunlight, bullous diseases,
pigmentation disorders, disorders of comification, pressure sores,
disorders of sweating, inflammatory reactions, xerosis, ichthyosis,
allergy, bum, wound, cut, and non-dermatological disorders, which
respond to transdermal delivery of said active agent.
79. (canceled)
80. The method of claim 66, wherein the active agent is selected
from the group consisting of an agent that influences hair growth,
a hair growth stimulating agent, and a hair growth inhibiting
agent.
81. (canceled)
82. (canceled)
83. The method of claim 66, further comprising a sunscreen
agent.
84. (canceled)
85. The method of claim 66, wherein the active agent is a
combination of a skin whitening agent and a sunscreen agent.
86. (canceled)
87. The method of claim 66, comprising an effective concentration
of a penetration enhancer.
Description
[0001] This application claims priority to Related Applications of
Israeli patent application No. 152486 filed Oct. 25, 2002 entitled
"Alcohol-free Cosmetic and Pharmaceutical Foam Carrier", and to
U.S. provisional patent application No. 60/495,546, filed Nov. 29,
2002, entitled "Cosmetic and Pharmaceutical Foam", which are
incorporated herein in their entirety.
FIELD OF THE INVENTION
[0002] The invention relates to an alcohol-free, cosmetic or
pharmaceutical foam carrier and its use. More specifically, the
invention relates to a cosmetic or pharmaceutical foam carrier
suitable for inclusion of both water soluble and oil soluble
pharmaceutical and cosmetic agents.
BACKGROUND OF THE INVENTION
[0003] External topical administration is an important route for
the administration of drugs in disease treatment. In external
topical administration, the drug is absorbed into and/or through
skin, mucous membrane or wound tissue. Many groups of drugs,
including, for example, antibiotic, anti-fungal, anti-inflammatory,
anesthetic, analgesic, anti-allergic, corticosteroid, retinoid and
anti-proliferative medications are preferably administered in
hydrophobic media, e.g. ointments or oils. However, due to the
undesirable consistency of these hydrophobic carriers, their use is
limited. For instance, ointments containing white petrolatum, e.g.,
Vaseline petroleum jelly, as the carrier often form an impermeable
barrier, so that metabolic products and excreta from the wounds to
which they are applied are not easily removed or drained away.
Furthermore, it is difficult for the active drug dissolved in the
carrier to pass through the white petrolatum barrier layer into the
wound tissue, so the efficacy of the drug is reduced.
[0004] In addition, ointments and creams often do not create an
environment for promoting respiration of the wound tissue and it is
not favorable to the normal respiration of the skin. An additional
disadvantage of petroleum jelly-based products relates to the
greasy feeling left following their topical application onto the
skin, mucosal membranes and wounds. Besides petroleum jelly,
hydrophobic pharmaceutical carriers now in use include liquid
paraffin, lanolin, beeswax, vegetable oil, glycerin monostearate,
higher alcohols, polyethylene glycol and some emulsifying agents,
which also have undesirable flow properties and skin feel.
[0005] Several hydrophobic liquid and semi-solid oils, e.g., mono-
and poly-unsaturated oils from vegetable and marine sources,
mineral oils, silicone oils, and liquid hydrophobic plant-derived
oils, are known for their therapeutic benefits when applied
topically, yet, their application in liquid form is not practical.
Oils can also contain essential nutritional constituents, such as
oil-soluble vitamins (e.g., vitamin A and vitamin E), minerals and
other therapeutically beneficial constituents. Another class of
therapeutic oils includes mineral and silicon oils useful for the
treatment of skin dehydration and other medical disorders, which
oils are liquid at ambient temperature. Such therapeutic oils
unfortunately, cannot be applied by users in amounts sufficient to
exert therapeutic affects because of they typically are liquid at
use temperatures.
[0006] Other pharmaceutical active ingredients are water-soluble
and require a water component in the carrier.
[0007] While semi-solid cosmetic and pharmaceutical formulations,
such as creams, lotions, gels and ointments are commonly used by
consumers, new forms are desirable, in order to achieve better
control of the application, while maintaining or bestowing the skin
beneficial properties of such products. Thus, the development of a
new composition, having breakable foam consistency when extruded
out of a container and liquid properties when applied onto the skin
is advantageous. Ideally a foam should contain hydrophobic
substances (solvents), which can act as emollients and provide the
skin with soothing and nourishing properties. However, such
hydrophobic solvents are difficult to formulate into a
lather-producing or foam-producing product because the hydrophobic
solvents interfere with the lather forming ability of the
surfactant. Furthermore, addition of oils and other emollients to
topical formulations can result in an unpleasant or annoying skin
residue.
[0008] Use of emulsions in foam compositions is known. Emulsion
systems provide a two-phase system including lipophilic or
hydrophobic components in one phase and hydrophilic components in
the second phase. The foamed emulsion typically is an oil-in-water
emulsion in which the hydrophobic component is dispersed in the
aqueous continuous phase. Surfactants for reducing surface tension
and emulsifiers for improving foam stability are included in the
foam composition.
[0009] Foams and, in particular, foam emulsions are complicated
systems which do not form under all circumstances. Slight shifts in
foam emulsion composition, such as by the addition of active
ingredients, may destabilize the foam. Furthermore, many emulsions
do not provide the high foam capacity, foam stability and/or
fast-breaking action under stress or temperatures that are desired
in a topical foam composition.
[0010] A particularly desirable type of oil-containing foam is such
wherein all or part of the oil phase comprises silicone oil.
Silicone oil is known for its skin protective features and its
incorporation in topical products is beneficial. However, it is not
obvious to produce silicone oil-based foams, since many silicone
oils possess anti-foaming properties.
[0011] U.S. Pat. No. 6,126,920 discloses treatment of various skin
diseases, and in particular, scalp psoriasis, using a foamable
pharmaceutical composition containing a corticosteroid active
substance, an aliphatic alcohol, water, a fatty alcohol, a
surface-active agent, a propellant and a buffering agent. The
foamable composition contains 40-90% w/w composition of an
aliphatic alcohol. U.S. Pat. No. 6,126,920 is typical of many
compositions that use aliphatic alcohols in the foam composition.
The alcohol promotes fast drying and thereby attempts to address
the sticky feeling left by many topical formulations after
application; however, alcohols, and in particular the methyl, ethyl
and isopropyl alcohols preferred in the '920 patent, are defatting
agents and may cause skin to become dry and cracked. Hence, the
presence of aliphatic alcohol in a therapeutic foam for external
topical administration as taught in U.S. Pat. No. 6,126,920 is
undesirable.
[0012] U.S. Pat. No. 5,536,743 to Borgman describes a buffered
non-flowing composition suitable for the treatment of bacterial
vaginosis which contains metronidazole. Suitable formulations
include oil-in-water emulsions including an internal oil phase of
about 10-40 wt % oil and anionic, cationic or nonionic surfactants.
Suitable components of the oleaginous phase include long chain
alcohols, esters, and acids, vegetable and animal oils and waxes.
No other stabilizing agents are disclosed for use in foam aerosol
compositions.
[0013] EP 0,598,412 describes a composition that is useful for skin
protection against drying and harsh environmental substances. The
protection is derived from the inclusion of
poly(tetrafluoroethylene) (PTFE) in the composition. The
composition includes low levels of both hydrophilic emollients and
hydrophobic emollients. The compositions include high levels of
surfactants, including ionic surfactants, and co-emulsifiers
resulting in thick emulsions which are not flowable, and thus
providing products which are inefficient foamers (or non-foaming)
and too thick for spreading over large skin areas.
[0014] U.S. Pat. No. 6,423,323 describes an aqueous foam emulsion.
The composition includes a hydrophobic phase including fatty acids,
emulsifiers and co-emulsifiers, and an aqueous phase containing
hydrophilic moisturizers and emulsifiers. An optional ingredient
according to U.S. Pat. No. 6,423,323 is one or more refatting
substances, in preferable concentrations of 0.5 to 2%, if the
product is to be used for normal skin; and 3 to 6% for dry skin.
Addition of high levels of co-emulsifiers such as fatty alcohols
and fatty acids suggest that the foam is not stable. No other
stabilizing agents are disclosed.
[0015] U.S. Pat. No. 5,635,469 describes a foamable cleansing
liquid composition comprising about 0.05% to about 10% of an
emollient, in addition to cleansing surfactants, humectants and
water soluble cationic or nonionic polymers, but no propellants.
Low density foams are achieved using a novel non-aerosol foam
dispenser. The foaming is achieved by operating a manual pump,
which is not convenient for operation. Emollients and humectants
are included to improve the level of hydration and/or lipid content
of the skin. However, the patent notes that emollients and
humectants interfere with the lather forming ability of the
surfactant.
[0016] U.S. Pat. No. 6,113,888 teaches a single water phase
composition comprising a self-tanning agent, a nitrogen-free
polymer, a nitrogen-free surfactant, and water.
[0017] U.S. Pat. No. 5,679,324 to Lisboa pertains to an aerosol
foamable fragrance composition, translucent in its pre-dispensed
state, which forms a fast breaking foam. Apparently the foam breaks
spontaneously upon discharging from an aerosol container (with no
need of any rubbing or sheer force application), thus, making is
impractical for spreading over a skin surface. The composition
contains surfactant, a propellant, a fragrance, a thickener, and a
cosmetic vehicle (preferably water) wherein the ratio of the
surfactant to propellant is from about 1:1 to about 1:10.
Emollients including silicone oils, mineral oils and hydrocarbon
oils may be included.
[0018] U.S. Pat. No. 6,251,369 discloses foamable dental fluoride
compositions containing a water-soluble fluoride component, whereby
said compositions include an oil in water emulsion. However, the
patent fails to specify the identity or concentration of the oil
component of the emulsion; and none of the compositions presented
in the examples contain any oil component.
[0019] U.S. Pat. No. 5,961,957 describes a barrier foam composition
comprising from 70 to 90% of water, from 7 to 9% of butane, from 2
to 4% of glyceryl monostearate, from 1.5 to 3.50% of dimethicone
copolyol (a water-soluble silicone compound), from 1 to 3% of
propane, from 0.5 to 2.5% of lanolin, from 0.5 to 2.5% of stearic
acid and from 0.05 to 1.05% of at least one of
methylchloroisothiazolinone and methylisothiazolinone.
[0020] A few dermatological foam products are available on the
market.
[0021] Olux.TM. Foam, produced by Connetics, Inc., contains
clobetasol propionate. Each gram of Olux.TM. Foam contains 0.5 mg
clobetasol propionate, USP, in a thermolabile foam, which consists
of ethanol (60%), purified water, propylene glycol, cetyl alcohol,
stearyl alcohol, polysorbate 60, citric acid, and potassium
citrate. It is dispensed from an aluminum can pressurized with a
hydrocarbon propellant (propane/butane). Luxiq.TM. is another
corticostroid foam medication, containng 1.2 mg betamethasone
valerate per gram, in a vehicle, comprising ethanol (60.4%),
purified water, propylene glycol, cetyl alcohol, stearyl alcohol,
polysorbate 60, citric acid, and potassium citrate, and pressurized
with a hydrocarbon propellant.
[0022] Cortifoam, a hydrocortisone acetate rectal foam is produced
by Schwartz Pharma GmbH, wherein the hydrocortisone is present at
10% in a foam vehicle. Nonmedicinal ingredients of Cortifoam
include cetyl alcohol, ethoxylated stearyl alcohol, methylparaben,
polyoxyethylene-10 stearyl ether, propylene glycol, propylparaben,
triethanolamine, water, and inert propellants, isobutene, and
propane.
[0023] Thus, foam compositions for topical treatment, containing
higher concentrations of oils, and do not comprise alcohol are
still desirable. Foam compositions that are robust and suitable for
inclusion of a wide range of active ingredients are desired.
SUMMARY OF THE INVENTION
[0024] Despite the commonly known fact that hydrophobic solvents
are difficult to formulate into a lather-producing or
foam-producing product and that addition of conventional
hydrophobic solvents interferes with the lather forming ability of
the surfactant, we have surprisingly discovered a series of
foamable carrier compositions, which, upon admixing with a
liquefied gas propellant in an aerosol container, produces a
foamable composition that is suitable for topical administration.
Upon discharge from an aerosol container, the composition forms a
breakable foam, which is rich and creamy in appearance, and show
very fine bubble structure. The foam does not break down
immediately upon discharge, however, it collapses to spread easily
onto a skin area upon slight rubbing.
[0025] In one or more embodiments of the present invention, the
alcohol-free cosmetic or pharmaceutical foamable carrier
composition includes water, a liquid, non-volatile hydrophobic
solvent, a foam adjuvant agent selected from the group consisting
of fatty acids and fatty alcohols, a surface-active agent and a
water gelling agent. Such foamable carriers, when placed in an
aerosol container and combined with a liquefied gas propellant,
create an oil in water emulsion, which, upon release from the
aerosol container, provides a therapeutically beneficial foam
product. The foam retains its structure for a time sufficient for a
user to apply and to rub the foam into the skin. The foam has a
very low yield strength and, hence, it breaks upon touch and makes
rubbing easy and efficient, and its application even.
[0026] In one or more embodiments of the present invention, the
foamable carrier composition the hydrophobic solvent content is
about 2-5% and has a composition as follows:
[0027] Class A Composition: [0028] about 2-5% hydrophobic solvent;
[0029] about 80-98% water; [0030] about 0.1% to 5% foam adjuvant
agent; [0031] about 0.1% to 5% surface-active agent; and [0032]
about 0.1% to 5% water gelling agent.
[0033] In one or more embodiments of the present invention, the
foamable composition the hydrophobic solvent content is about 5-10%
and has a composition as follows:
[0034] Class B Composition: [0035] about 5-10% hydrophobic solvent;
[0036] about 75-95% water; [0037] about 0.1% to 5% foam adjuvant
agent; [0038] about 0.1% to 5% surface-active agent; and [0039]
about 0.1% to 5% water gelling agent.
[0040] In one or more embodiments of the present invention, the
foamable composition the hydrophobic solvent content is about
10-20% and has a composition as follows:
[0041] Class C Composition: [0042] about 10-20% hydrophobic
solvent; [0043] about 60-90% water; [0044] about 0.1% to 5% foam
adjuvant agent; [0045] about 0.1% to 5% surface-active agent; and
[0046] about 0.1% to 5% water gelling agent.
[0047] In one or more embodiments of the present invention, the
foamable composition the hydrophobic solvent content is about
20-75% and has a composition as follows:
[0048] Class A Composition: [0049] about 20-75% hydrophobic
solvent; [0050] about 25-75% water; [0051] about 0.1% to 5% foam
adjuvant agent; [0052] about 0.1% to 5% surface-active agent; and
[0053] about 0.1% to 5% water gelling agent.
[0054] All % values are provided on a weight (w/w) basis, based on
the composition with out propellant (unless otherwise
specified).
[0055] The cosmetic or pharmaceutical foamable carrier composition
is liquid. The foamable of the present invention does not contain
short chain aliphatic alcohols, making it non-irritating and
non-drying. Alcohols penetrate the skin's protective barrier and
break down the intercellular matrix. In a recent publication by the
American Academy of Dermatology (AAD), titled "Facing the Facts
about Skin Care Products" it is stated "[i]ndividuals with dry skin
should avoid astringents and any product with alcohol because they
easily strip away moisture from the skin" (see:
www.aad.org/PressReleases FacingFacts.html). Another AAD
publication, titled "Sensitive About Your Skin?", recommends to
"[a]void solvents that penetrate the skin including, propylene
glycol and ethanol" (see:
www.aad.org/PressReleases/sensitive.html).
[0056] The alcohol-free foam carrier is formulated as an
oil-in-water or water-in-oil emulsion, so that it is suitable for
inclusion of either water-soluble and oil soluble active agents (or
both). The foamable carrier composition of the present invention,
when admixed with a propellant substance in an amount of about
5-25% by weight of the total composition in an aerosol container,
produces lightweight breakable foam, suitable for facile
application onto the skin, and other body areas, which may accept
topically-applied products. Since the propellant, in the
pressurized container is in liquid state, upon admixing the
foamable carrier composition with the propellant, a stable
emulsion, comprising the oil and the propellant (jointly as the
"oil phase" component of such emulsion) is formed.
[0057] In one or more embodiments of the present invention, an
alcohol-free cosmetic or pharmaceutical product is provided. The
product includes a foam carrier composition according to one or
more embodiments of the present invention and an active cosmetic or
pharmaceutical ingredient in a therapeutically effective
concentration. Cosmetic and pharmaceutical agents can be included
in each of the compositions described above and in the detailed
description that follows. Pharmaceutical products are intended for
topical treatment of human and animal skin disorders, or any other
disorder, that requires topical application of a drug. Cosmetic
products are intended for beautifying the skin and improving its
appearance.
[0058] Cosmetic and medical disorders that are best treated using
the alcohol-free foam carrier and the alcohol-free cosmetic or
pharmaceutical product are identified, and the advantages of such
carrier and products is demonstrated as compared to currently
available options.
[0059] The foam of the present invention is advantageous to current
options, for one or more of the following reasons: [0060] (1) The
foam is lightweight and thus, economical. [0061] (2) The foam
contains a hydrophobic solvent, in any desirable concentration,
which provides a refatting and skin soothing effect, as well as a
carrier for hydrophobic active agents. [0062] (3) The foam contains
silicone oil in a therapeutically effective concentration [0063]
(4) The foam includes active agent, both water soluble and oil
soluble. [0064] (5) The foam is easily spreadable, allowing
treatment of large areas such as the arms, back, legs and the
breast. [0065] (6) Due to its flow properties, it spreads
effectively into folds and wrinkles, providing uniform distribution
of the active agent without the need of extensive rubbing and
absorbs into the skin.
BRIEF DESCRIPTION OF THE DRAWINGS
[0066] A more complete appreciation of the present invention and
many of its advantages will be understood by reference to the
following detailed description when considered in connection with
the following drawings, which are presented for the purpose of
illustration only are not intended to limit the scope of the
appended claims, and in which:
[0067] FIG. 1 illustrates the improvement in the treatment of
psoriasis using Bethasone valerate 0.12% foam; and
[0068] FIG. 2 illustrates the improvement in the treatment of
atopic dermatitis using Bethasone valerate 0.12% foam.
DETAILED DESCRIPTION OF THE INVENTION
[0069] Hydrophobic Solvent
[0070] A hydrophobic solvent according to the present invention is
a liquid material having solubility in distilled water at ambient
temperature of less than about 1 gm per 100 mL, more preferable
less than about 0.5 gm per 100 mL, and most preferably less than
about 0.1 gm per 100 mL. It is liquid at ambient temperature.
[0071] The total content of hydrophobic solvent may vary from 2% to
75% (w/w) of the foamable composition. However, different ranges
(herein "composition classes A-D") have been designated, in order
to facilitate a choice of an appropriate class, according to the
anticipated cosmetic or pharmaceutical need. As a rule of thumb,
higher hydrophobic solvent concentrations are more appropriate for
the treatment of dry skin, and/or for the treatment of a disease,
which is more responsive to drugs delivered in an oily vehicle.
Likewise, the higher oil-content composition classes provide an
enhanced occlusive effect, which in turn induces the skin
penetration of an active agent. Another consideration relates to
user acceptance of a product containing a high concentration of the
hydrophobic solvent (from about 25% of the composition), which
would leave some oily feeling post-application. Thus, a particular
composition of the present invention is selected having a
hydrophobic solvent concentration in view of the target population
and its specific needs.
[0072] In one or more embodiments of the present invention, the
hydrophobic solvent is mineral oil. Mineral oil (Chemical Abstracts
Service Registry number 8012-95-1) is a mixture of aliphatic,
naphthalenic, and aromatic liquid hydrocarbons that are derived
from petroleum. It is typically liquid; its viscosity is in the
range of about 35 CST to about 100 CST (at 40.degree. C.), and its
pour point (the lowest temperature at which an oil can be handled
without excessive amounts of wax crystals forming) is below
0.degree. C. By contrast, white petrolatum, also termed "Vaseline",
is disadvantageous, due to its waxy nature. It is known to leave
waxy and sticky feeling after application and occasionally stain
cloths. Thus, white petrolatum and other semi-solid oils are not a
preferred hydrophobic solvent according to the present
invention.
[0073] Yet another preferred hydrophobic solvents are liquid oils
from vegetable, marine or animal sources. By way of example, the
unsaturated oil may be selected from the group consisting of olive,
corn, soybean, canola, cottonseed, coconut, sesame, sunflower,
borage seed, syzigium aromaticum, hempseed, herring, cod-liver,
salmon, flaxseed, wheat germ and evening primrose oils and mixtures
thereof, at any proportion.
[0074] A particularly preferred class of oils includes
polyunsaturated oils, e.g., esters, and in particular glyceryl
esters, of omega-3 and omega-6 fatty acids. Examples of such
polyunsaturated fatty acids are linoleic and linolenic acid,
gamma-linoleic acid (GLA), eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA). Thus, in one or more embodiments of the
present invention the hydrophobic solvent includes at least 6% by
weight foamable composition of an oil selected from omega-3 oil,
omega-6 oil, and mixtures thereof.
[0075] Another class of oils suitable for use as a phydrophobic
solvent is liquid hydrophobic plant-derived oils, or essential
oils, e.g. "therapeutic oils" containing active biologically
occurring molecules that have a therapeutic effect when applied
topically. Examples of such oils include rosehip oil, which contain
retinoids and is known to reduce acne and post-acne scars, and tea
tree oil, which possess antibacterial, antifungal and antiviral
properties. Other examples of essential oils are oils of basil,
camphor, cardamom, carrot, citronella, clary sage, clove, cypress,
frankincense, ginger, grapefruit, hyssop, jasmine, lavender, lemon,
mandarin, marjoram, myrrh, neroli, nutmeg, petitgrain, sage,
tangerine, vanilla, verbena, as well as any other therapeutically
beneficial oil, know in the art of herbal medication.
[0076] In one or more embodiments of the present invention, the
hydrophobic solvent is an "emollient". An emollient is a
hydrophobic agent that softens, smoothens and improves lipid
content of the skin or other mucous membranes. In one or more
embodiments of the present invention, the emollient is a liquid.
Without derogating the generality of this definition, examples of
suitable emollients for use include isostearic acid derivatives,
isopropyl palmitate, lanolin oil, diisopropyl dimerate, diisopropyl
adipate, dimethyl isosorbide, maleated soybean oil, octyl
palmitate, isopropyl isostearate, cetyl lactate, cetyl ricinoleate,
tocopheryl acetate, acetylated lanolin alcohol, cetyl acetate,
phenyl trimethicone, glyceryl oleate, tocopheryl linoleate, wheat
germ glycerides, arachidyl propionate, myristyl lactate, decyl
oleate, propylene glycol ricinoleate, isopropyl lanolate,
pentaerythrityl tetrastearate, neopentylglycol
dicaprylate/dicaprate, hydrogenated coco-glycerides, isononyl
isononanoate, isotridecyl isononanoate, myristyl myristate,
triisocetyl citrate, octyl dodecanol, octyl hydroxystearate and
mixtures thereof. Other examples of other suitable emollients can
also be found in the Cosmetic Bench Reference, pp. 1.19-1.22
(1996). In one or more embodiments, the hydrophobic solvent is a
mixture of a mineral oil or silicone oil and an emollient.
[0077] In one or more embodiments of the present invention,
silicone oil is a component of the hydrophobic solvent. Silicone
oils are used in the foamable compositions due to their known skin
protective and occlusive properties. Suitable silicone oils for use
in the invention include non-volatile silicones, such as polyalkyl
siloxanes, polyaryl siloxanes, polyalkylaryl siloxanes and
polyether siloxane copolymers, polydimethylsiloxanes (dimethicones)
and poly(dimethylsiloxane)-(diphenyl-siloxane) copolymers. These
are preferably chosen from cyclic or linear polydimethylsiloxanes
containing from about 3 to about 9, preferably from about 4 to
about 5, silicon atoms. Volatile silicones such as cyclomethicones
can also be used. Water-soluble silicones, such as dimethicone
copolyol are not included in the definition of silicone oils (as
hydrophobic solvents) according to the present invention.
[0078] In one or more embodiments of the present invention, the
composition comprises at least 2% (w/w foamable composition)
silicone oil, alone or as part of the hydrophobic solvent. Yet, in
other embodiments, the composition comprises at least 5% (w/w)
silicone oil alone or as part of the hydrophobic solvent.
[0079] The hydrophobic solvent of the present invention may
comprise a mixture of two or more of the above hydrophobic solvents
in any proportion.
[0080] Foam Adjuvant Agents
[0081] Foam adjuvants are included in the foamable compositions of
the present invention to increase the foaming capacity of
surfactants and/or to stabilize the foam. In one or more
embodiments of the present invention, the foam adjuvant agents
includes fatty alcohols having 15 or more carbons in their carbon
chain, such as cetyl alcohol and stearyl alcohol (or mixtures
thereof). Other examples of fatty alcohols are arachidyl alcohol
(C20), behenyl alcohol (C22), 1 -triacontanol (C30), as well as
alcohols with longer carbon chains (up to C50). Fatty alcohols,
derived from beeswax, including a mixture of alcohols, a majority
of which has at least 20 carbon atoms in their carbon chain, are
especially well suited as foam adjuvant agents according to the
present invention. The concentration of the fatty alcohol, required
to support the foam system is inversely related to the length of
its carbon chains.
[0082] In one or more embodiments of the present invention, the
foam adjuvant agent includes fatty acids having 16 or more carbons
in their carbon chain, such as hexadecanoic acid (C16) stearic acid
(C18), arachidic acid (C20), behenic acid (C22), octacosanoic acid
(C28), as well as fatty acids with longer carbon chains (up to
C50), or mixtures thereof.
[0083] Optionally, the carbon atom chain of the fatty alcohol or
the fatty acid may have at least one double bond. A further class
of foam adjuvant agent according to the present invention comprises
a long chain fatty alcohol or fatty acid, wherein the carbon atom
chain is branched. The carbon chain of the fatty acid or fatty
alcohol can be substituted with a hydroxyl group, such as
12-hydroxy stearic acid.
[0084] The foam adjuvant agent according to one or more embodiments
of the present invention includes a mixture of fatty alcohols,
fatty acids and hydroxy fatty acids and derivatives thereof in any
proportion, providing that the total amount is 0.1% to 5% (w/w) of
the carrier mass. More preferably, the total amount is 0.4% - 2.5%
(w/w) of the carrier mass.
[0085] While fatty alcohols and fatty acids serve to stabilize the
resultant foam composition, they often provide additional
therapeutic properties. Long chain saturated and mono unsaturated
fatty alcohols, e.g., stearyl alcohol, erycyl alcohol, arachidyl
alcohol and docosanol have been reported to possess antiviral, anti
infective, anti-proliferative and anti-inflammatory properties
(U.S. Pat. No. 4,874,794). Longer chain fatty alcohols, e.g.,
tetracosanol, hexacosanol, heptacosanol, octacosanol, triacontanol,
etc. are also known for their metabolism modifying properties and
tissue energizing properties. Long chain fatty acids have also been
reported to possess anti-infective characteristics. Thus, the
pharmaceutical or cosmetic carrier, containing the foam adjuvant
agent of the present invention provides an extra therapeutic
benefit in comparison with currently used vehicles, which are inert
and non-active.
[0086] Surface-active Agents
[0087] Surface-active agents, according to the present invention
include any agent linking oil and water in the composition.
[0088] The surface-active agent is suitably selected from anionic,
cationic, nonionic, zwitterionic, amphoteric and ampholytic
surfactants, as well as mixtures of these surfactants. Such
surfactants are well known to those skilled in the pharmaceutical
and cosmetic formulation art. Nonlimiting examples of possible
surfactants include polysorbates, such as polyoxyethylene (20)
sorbitan monostearate (Tween 60) and poly(oxyethylene) (20)
sorbitan monooleate (Tween 80); poly(oxyethylene) (POE) fatty acid
esters, such as Myrj 45, Myri 49 and Myrj 59; poly(oxyethylene)
alkylyl ethers, such as poly(oxyethylene) cetyl ether,
poly(oxyethylene) palmityl ether, polyethylene oxide hexadecyl
ether, polyethylene glycol cetyl ether, brij 38, brij 52, brij 56
and brij W1; sucrose esters, partial esters of sorbitol and its
anhydrides, such as sorbitan monolaurate and sorbitan monolaurate;
mono or diglycerides, isoceteth-20, sodium methyl cocoyl taurate,
sodium methyl oleoyl taurate, sodium lauryl sulfate,
triethanolamine lauryl sulfate and betaines.
[0089] A combination of surface active agents is possible. Any
surface-active agent or combinations thereof may be used as
surface-active agent. According to one or more embodiments of the
present invention, the surface-active agent (or agents) has an HLB
of higher than 9.
[0090] In one or more embodiments of the present invention, the
surface-active agent is selected from the groups of non ionic
surfactants, cationic surfactants, amphoteric and zwitterionic
surfactants, and, in particular, the surface-active agent is a
non-ionic surfactant. Ionic surfactants (including cationic,
anionic, amphotheric and zwitterionic surfactants) are known to be
skin irritants. Therefore, non-ionic surfactants are preferred in
applications including sensitive skin such as found in most
dermological disorders. We have surprisingly found that non-ionic
surfactants alone provide foams of excellent quality, i.e. a score
of "E" according to the grading scale discussed below.
[0091] In one or more embodiments of the present invention, the
surface active agent is solely non-ionic, comprising one or more
non-ionic surfactants.
[0092] In one or more embodiments of the present invention, the
surface active agent include a ratio of non-ionic surfactants to
ionic surfactants in the range of 100:1 to 6:1; in some embodiments
the non-ionic to ionic surfactant ratio is greater than 6:1, or
greater than 8:1; or greater than 14:1, or greater than 16:1, or
greater than 20:1.
[0093] Exemplary non-ionic surfactants include polyethoxylated
fatty acids, fatty acid diesters, polyethylene glycol glycerol
fatty acid esters, alcohol-oil transesterification products,
polyglycerized fatty acids, sterol and sterol derivatives,
polyethylene glycol sorbitan fatty acid esters, polyethylene glycol
alkyl ethers, sugar esters, polyethylene glycol alkyl phenols,
polyoxyethylene-polyoxypropylene block copolymers, sorbitan fatty
acid esters and lower alcohol fatty acid esters.
[0094] Although polyethylene glycol (PEG) itself does not function
as a surfactant, a variety of PEG-fatty acid esters have useful
surfactant properties. Exemplary monoesters include esters of
lauric acid, oleic acid, and stearic acid, e.g., PEG-8 laurate,
PEG-8 oleate, PEG-8 stearate, PEG-9 oleate, PEG-10 laurate, PEG-10
oleate, PEG-12 laurate, PEG-12 oleate, PEG-15 oleate, PEG-20
laurate and PEG-20 oleate. Polyethylene glycol fatty acid diesters
suitable for use as non-ionic surfactants in the compositions of
the present invention include PEG-20 dilaurate, PEG-20 dioleate,
PEG-20 distearate, PEG-32 dilaurate and PEG-32 dioleate. Suitable
polyethylene glycol glycerol fatty acid esters include PEG-20
glyceryl laurate, PEG-30 glyceryl laurate, PEG-40 glyceryl laurate,
PEG-20 glyceryl oleate, and PEG-30 glyceryl oleate.
[0095] A large number of surfactants of different degrees of
hydrophobicity or hydrophilicity can be prepared by reaction of
alcohols or polyalcohols with a variety of natural and/or
hydrogenated oils. Most commonly, the oils used are castor oil or
hydrogenated castor oil, or an edible vegetable oil such as corn
oil, olive oil, peanut oil, palm kernel oil, apricot kernel oil, or
almond oil. Preferred alcohols include glycerol, propylene glycol,
ethylene glycol, polyethylene glycol, sorbitol, and
pentaerythritol. Among these alcohol-oil transesterified
surfactants, preferred hydrophilic surfactants are PEG-35 castor
oil (Incrocas-35), PEG-40 hydrogenated castor oil (Cremophor RH
40), PEG-25 trioleate (TAGAT.RTM. TO), PEG-60 corn glycerides
(Crovol M70), PEG-60 almond oil (Crovol A70), PEG-40 palm kernel
oil (Crovol PK70), PEG-50 castor oil (Emalex C-50), PEG-50
hydrogenated castor oil (Emalex HC-50), PEG-8 caprylic/capric
glycerides (Labrasol), and PEG-6 caprylic/capric glycerides
(Softigen 767). Preferred hydrophobic surfactants in this class
include PEG-5 hydrogenated castor oil, PEG-7 hydrogenated castor
oil, PEG-9 hydrogenated castor oil, PEG-6 corn oil (Labrafil.RTM. M
2125 CS), PEG-6 almond oil (Labrafil.RTM. M 1966 CS), PEG-6 apricot
kernel oil (Labrafil.RTM. M 1944 CS), PEG-6 olive oil
(Labrafil.RTM. M 1980 CS), PEG-6 peanut oil (Labrafil.RTM. M 1969
CS), PEG-6 hydrogenated palm kernel oil (Labrafil.RTM. M 2130 BS),
PEG-6 palm kernel oil (Labrafil.RTM. M 2130 CS), PEG-6 triolein
(Labrafil.RTM. b M 2735 CS), PEG-8 corn oil (Labrafil.RTM. WL 2609
BS), PEG-20 corn glycerides (Crovol M40), and PEG-20 almond
glycerides (Crovol A40). The latter two surfactants are reported to
have HLB values of 10, which is generally considered to be the
approximate border line between hydrophilic and hydrophobic
surfactants.
[0096] Alcohol-oil transesterification derivatives of oil soluable
vitamins (e.g., vitamins A, D, E, K, etc.), such as tocopheryl
PEG-100 succinate (TPGS, available from Eastman), are also suitable
surfactants.
[0097] Polyglycerol esters of fatty acids are also suitable
non-ionic surfactants for the present invention. Among the
polyglyceryl fatty acid esters, exemplary use hydrophobic
surfactants include polyglyceryl oleate (Plurol Oleique),
polyglyceryl-2 dioleate (Nikkol DGDO), and polyglyceryl-10
trioleate. Preferred hydrophilic surfactants include
polyglyceryl-10 laurate (Nikkol Decaglyn 1-L), polyglyceryl-10
oleate (Nikkol Decaglyn 1-0), and polyglyceryl-10 mono, dioleate
(Caprol.RTM. PEG 860), Polyglyceryl polyricinoleates (Polymuls) are
hydrophilic and hydrophobic surfactants of this class.
[0098] Sterols and derivatives of sterols are suitable surfactants
for use in the present invention. These surfactants can be
hydrophilic or hydrophobic. Preferred derivatives include the
polyethylene glycol derivatives. An exemplary hydrophobic
surfactant in this class is cholesterol. An exemplary hydrophilic
surfactant in this class is PEG-24 cholesterol ether (Solulan
C-24).
[0099] A variety of PEG-sorbitan fatty acid esters are suitable for
use as non-ionic surfactants in the present invention. In general,
these surfactants are hydrophilic, although several hydrophobic
surfactants of this class can be used. Among the PEG-sorbitan fatty
acid esters, exemplary hydrophilic surfactants include PEG-20
sorbitan monolaurate (Tween-20), PEG-20 sorbitan monopalmitate
(Tween-40), PEG-20 sorbitan monostearate (Tween-60), and PEG-20
sorbitan monooleate (Tween-80).
[0100] Ethers of polyethylene glycol and alkyl alcohols are
suitable non-ionic surfactants for use in the present invention.
Exemplary hydrophobic ethers include PEG-3 oleyl ether (Volpo 3)
and PEG-4 lauryl ether (Brij 30).
[0101] The polyoxyethylene-polyoxypropylene (POE-POP) block
copolymers are a unique class of polymeric surfactants. The unique
structure of the surfactants, with hydrophilic POE and hydrophobic
POP moieties in well-defined ratios and positions, provides a wide
variety of surfactants suitable for use in the present invention.
These surfactants are available under various trade names,
including Synperonic PE series (ICI), Pluronic.RTM. series (BASF),
Emkalyx, Lutrol (BASF), Supronic, Monolan, Pluracare, and Plurodac.
The generic term for these polymers is "poloxamer" (CAS 9003-11-6).
Exemplary hydrophilic surfactants of this class include Poloxamers
108, 188, 217, 238, 288, 338, and 407. Exemplary hydrophobic
surfactants in this class include Poloxamers 124, 182, 183, 212,
331, and 335.
[0102] Sorbitan esters of fatty acids are suitable non-ionic
surfactants for use in the present invention. Among these esters,
preferred hydrophobic surfactants include sorbitan monolaurate
(Arlacel 20), sorbitan monopalmitate (Span-40), sorbitan monooleate
(Span-80), sorbitan monostearate, and sorbitan tristearate.
[0103] Esters of lower alcohols (C.sub.2 to C.sub.4) and fatty
acids (C.sub.8 to C.sub.18) are suitable non-ionic surfactants for
use in the present invention. Among these esters, preferred
hydrophobic surfactants include ethyl oleate (Crodamol EO),
isopropyl myristate (Crodamol IPM), and isopropyl palmitate
(Crodamol IPP).
[0104] In one or more embodiments of the present invention, the
surface-active agent comprise mono-, di- and tri-esters of sucrose
with food fatty acids (sucrose esters), prepared from sucrose and
methyl and ethyl esters of food fatty acids or by extraction from
sucroglycerides. Exemplary sucrose esters include sucrose
monopalmitate and sucrose monolaurate. Suitable sucrose esters
include those having a high monoester content, which have higher
HLB values.
[0105] In one or more embodiments of the present invention, a
combination of a non-ionic surfactant and an anionic surfactant
(such as sodium lauryl sulphate) is employed, at a ratio of between
1:1 and 20:1, or at a ratio of 4:1 to 10:1. The resultant foam has
a low specific gravity, e.g., less than 0.1 g/ml, which upon
rubbing (shear stress) onto the skin collapses easily, to allow
facile absorption.
[0106] Unlike prior art foamable compositions, the total surfactant
employed to obtain a foam that is stable, of low specific gravity
and has a fine bubble structure is low. Lower surfactant levels,
particularly of ionic surfactants, are preferred to reduce skin
irritations. Total surfactant is in the range of 0.1 to 5.0 wt % of
the foamable composition, and is typically less than 2 wt %, or
even less than 1 wt %.
[0107] Water Gelling Agents The water gelling agent according to
one or more embodiments of the present invention stablizes the
acqueons phase by, for example, increasing viscosity and linking
capability. Exemplary water gelling agents that can be used in
accordance with one or more embodiments of the present invention
include for example, but are not limited to, naturally-occurring
polymeric materials such as, locust bean gum, sodium alginate,
sodium caseinate, egg albumin, gelatin agar, carrageenin gum sodium
alginate, xanthan gum, quince seed extract, tragacanth gum, starch,
chemically modified starches and the like, semi-synthetic polymeric
materials such as cellulose ethers (e.g. hydroxyethyl cellulose,
methyl cellulose, carboxymethyl cellulose, hydroxy propylmethyl
cellulose), polyvinylpyrrolidone, polyvinylalcohol, guar gum,
hydroxypropyl guar gum, soluble starch, cationic celluloses,
cationic guars and the like and synthetic polymeric materials such
as carboxyvinyl polymers, polyvinylpyrrolidone, polyvinyl alcohol
polyacrylic acid polymers, polymethacrylic acid polymers, polyvinyl
acetate polymers, polyvinyl chloride polymers, polyvinylidene
chloride polymers and the like. Mixtures of the above compounds are
contemplated.
[0108] Further exemplary water gelling agents include the acrylic
acid/ethyl acrylate copolymers and the carboxyvinyl polymers sold,
for example, by the B.F. Goodrich Company under the trademark of
Carbopol Registered TM resins. These resins consist essentially of
a colloidal water-soluble polyalkenyl polyether crosslinked polymer
of acrylic acid crosslinked with from 0.75% to 2% of a crosslinking
agent such as polyallyl sucrose or polyallyl pentaerythritol.
Examples include Carbopol 934, Carbopol 940, Carbopol 950, Carbopol
980, Carbopol 951 and Carbopol 981. Carbopol 934 is a water-soluble
polymer of acrylic acid crosslinked with about 1% of a polyallyl
ether of sucrose having an average of about 5.8 allyl groups for
each sucrose molecule.
[0109] The gelling agent is present in an amount in the range of
about 0.1% to about 5.0 wt % of the foamable composition. In one or
more embodiments, it is typically less than 1 wt % of the foamable
composition.
[0110] "Alcohol free"
[0111] Unlike the composition disclosed in U.S. Pat. No. 6,126,920,
which contains a 40-90 wt % aliphatic alcohol, the composition of
the present invention does not contain such amount alcohols. For
the purpose of the present application, the term "alcohol free"
shall mean that the composition contains no more than an incidental
amount of an aliphatic alcohol, e.g. less than about 7.5% of any
aliphatic alcohol, having one to six carbon atoms in their carbon
backbone, or no more than 7.5% of any mixture of such aliphatic
alcohols. Alcohols at these low levels are not considered to have a
negative effect on skin or mucous membranes. In one or more
embodiments, the foamable compositions do not contain any
alcohol.
[0112] Optional Ingredients
[0113] The pharmaceutical or cosmetic foam carrier of the present
invention may further optionally comprise a variety of
pharmaceutical or cosmetic ingredients, which are added in order to
fine-tune the consistency of the formulation, protect the
formulation components from degradation and oxidation and bestow
their cosmetic acceptability. Such excipients, may be selected, for
example, from the group consisting of diglycerides, triglycerides,
stabilizing agents, antioxidants, humectants, flavoring, colorant
and odorant agents and other formulation components, used in the
art of pharmaceutical and cosmetic formulary. A pharmaceutical or
cosmetic composition manufactured using the foam carrier according
to the present invention is very easy to use. When applied onto the
afflicted body surface of humans or animals, it is in a foam state,
allowing free application without spillage. Upon further
application of a mechanical force, e.g., by rubbing the composition
onto the body surface, it freely spreads on the surface and is
rapidly absorbed.
[0114] Propellant Aerosol
[0115] Aerosol propellants are used to generate and administer the
foamable composition as a foam. The total composition including
propellant, foamable compositions and optional ingredients is
referred to as the foamable carrier. The propellant makes up about
5-25 wt % of the foamable carrier. Examples of suitable propellants
include volatile hydrocarbons such as butane, propane, isobutane or
mixtures thereof, and fluorocarbon gases.
[0116] Composition and Foam Physical Characteristics
[0117] 1. Composition Flow Properties:
[0118] It is important to have a composition, including water,
hydrophobic solvents, formulation excipients and propellant, in a
stable emulsion, which ascertain acceptable shelf-life of the
product.
[0119] Yet, another crucial property is that said composition has
to be free flowing, since otherwise, it cannot flow through the
dip-tube of the aerosol container and create acceptable foam. It
has been noted that in the context of the composition of the
present invention, compositions comprising semi-solid hydrophobic
solvents, e.g., white petrolatum, are excessively viscous and
demonstrate poor flowability.
[0120] The combination of a surface active agent, foaming adjuvant
and water gelling agent according to one or more embodiments of the
invention provides a low specific gravity foam having superior flow
properties and sheer breakability (among other attributes).
According to one or more embodiments of the present invention, the
total amount of surface active agent, foaming adjuvant and water
gelling agent, in combination does not exceed 8% (w/w) of foamable
composition. In other embodiments, the combined amounts of surface
active agent, foaming adjuvant and water gelling agent is less than
5% (w/w) of foamable composition. The low solids content improves
the flow properties of the foam, reduces unpleasant skin residue
and reduces the cost of manufacture. As is demonstrated herein, the
foam quality and foam breakability is excellent, despite the low
levels of these components in the foam.
[0121] 2. Foam Properties:
[0122] The following scale for foam quality is used to evaluate
foams.
[0123] E (excellent): very rich and creamy in appearance, does not
show any bubble structure or shows a very fine (small) bubble
structure.
[0124] G (good): rich and creamy in appearance, very small bubble
size, "dulls" more rapidly than an excellent foam.
[0125] FG (fairly good): a moderate amount of creaminess
noticeable, bubble structure is noticeable.
[0126] F (fair): very little creaminess noticeable, larger bubble
structure than a "fairly good" foam.
[0127] P (poor): no creaminess noticeable, large bubble
structure.
[0128] VP (very poor): dry foam, large very dull bubbles, difficult
to spread on the skin.
[0129] Foams, adequate for topical administration according to the
present invention have to be of quality grade E or G, upon release
from the aerosol container. Smaller bubbles mean more stable foam,
which does not collapse spontaneously immediately upon discharge
from the container. The finer foam structure looks and feels
smoother, thus increasing its usability and appeal.
[0130] A crucial aspect of foam properties, according to the
present invention is breakability. Sheer-force breakability of the
foam, as attained by the composition of the present invention is
clearly advantageous to thermally-induced breakability, present,
for example in U.S. Pat. No. 6,126,920, and the respective Olux and
Luxiq products, as demonstrated by the fact that according to the
use instructions of Olux and Luxiq, the foam cannot be applied on
the hand and afterwards delivered to the afflicted area, since it
immediately collapses upon exposure to skin temperature.
[0131] Yet, another important property is specific gravity of the
foam, as measured upon release from the aerosol can. Typically,
foams according to the present invention have specific gravity of
less than 0.1 g/mL and more preferably, less than 0.05 g/mL.
FIELDS OF PHARMACEUTICAL APPLICATIONS
[0132] By including an appropriate therapeutic agent in the
foamable carrier, the foam composition of the present invention is
useful in the therapy of a variety of dermatological disorders
(also termed "dermatoses"), including, in a non-limiting exemplary
manner:
[0133] Dermatitis [0134] Contact Dermatitis [0135] Atopic
Dermatitis [0136] Seborrheic Dermatitis [0137] Nummular Dermatitis
[0138] Chronic Dermatitis Of The Hands And Feet [0139] Generalized
Exfoliative Dermatitis [0140] Stasis Dermatitis [0141] Lichen
Simplex Chronicus
[0142] Bacterial Infections [0143] Cellulitis [0144] Acute
Lymphangitis [0145] Lymphadenitis [0146] Erysipelas [0147]
Cutaneous Abscesses [0148] Necrotizing Subcutaneous Infections
[0149] Staphylococcal Scalded Skin Syndrome [0150] Folliculitis
[0151] Furuncles [0152] Hidradenitis Suppurativa [0153] Carbuncles
[0154] Paronychial Infections [0155] Erythrasma
[0156] Fungal Infections [0157] Dermatophyte Infections [0158]
Yeast Infections
[0159] Parasitic Infections [0160] Scabies [0161] Pediculosis
[0162] Creeping Eruption
[0163] Viral Infections
[0164] Disorders of Hair Follicles and Sebaceous Glands [0165] Acne
[0166] Rosacea [0167] Perioral Dermatitis [0168] Hypertrichosis
(Hirsutism) [0169] Alopecia, including male pattern baldness,
alopecia areata, alopecia universalis and alopecia totalis [0170]
Pseudofolliculitis Barbae [0171] Keratinous Cyst
[0172] Scaling Papular Diseases [0173] Psoriasis [0174] Pityriasis
Rosea [0175] Lichen Planus [0176] Pityriasis Rubra Pilaris
[0177] Benign Tumors [0178] Moles [0179] Dysplastic Nevi [0180]
Skin Tags [0181] Lipomas [0182] Angiomas [0183] Pyogenic Granuloma
[0184] Seborrheic Keratoses [0185] Dermatofibroma [0186]
Keratoacanthoma [0187] Keloid
[0188] Malignant Tumors [0189] Basal Cell Carcinoma [0190] Squamous
Cell Carcinoma [0191] Malignant Melanoma [0192] Paget's Disease Of
The Nipples [0193] Kaposi's Sarcoma
[0194] Reactions To Sunlight [0195] Sunburn [0196] Chronic Effects
of Sunlight [0197] Photosensitivity
[0198] Bullous Diseases [0199] Pemphigus [0200] Bullous Pemphigoid
[0201] Dermatitis Herpetiformis [0202] Linear Immunoglobulin A
Disease
[0203] Pigmentation Disorders [0204] Hypopigmentation [0205]
Vitiligo [0206] Albinism [0207] Postinflammatory hypopigmentation
[0208] Hyperpigmentation [0209] Melasma (chloasma) [0210]
Drug-induced hyperpigmentation [0211] Postinflammatory
hyperpigmentation
[0212] Disorders of Cornification [0213] Ichthyosis [0214]
Keratosis Pilaris [0215] Calluses And Corns [0216] Actinic
keratosis
[0217] Pressure Sores
[0218] Disorders of Sweating
[0219] Inflammatory reactions [0220] Drug Eruptions [0221] Toxic
Epidermal Necrolysis [0222] Erythema Multiforme [0223] Erythema
Nodosum [0224] Granuloma Annulare
[0225] In one or more embodiments of the present invention, the
foam composition of the present invention is useful in the therapy
of non-dermatological disorders, which respond to transdermal
delivery of an active agent. By way of example, such disorders
include localized pain in general, as well as joint pain, muscle
pain, back pain, rheumatic pain, arthritis, ostheoarthritis and
acute soft tissue injuries and sports injuries. Other disorders of
this class include conditions, which respond to hormone therapy,
such as hormone replacement therapy, transdermal nicotine
administration, and other respective disorders, known in the art of
drug delivery. The foam composition of the present invention is
also useful in the delivery of local anesthetic agents.
ACTIVE PHARMACEUTICAL AGENTS (DRUGS)
[0226] The active pharmaceutical agents, also referred to as
"drug(s)", may consist of a single drug or a combination of drugs
that can be dissolved in the water phase or the hydrophobic phase
of the carrier composition. Examples of such drugs are antibiotic,
antibacterial, antifungal, antiviral, antiinflammatory, anesthetic,
analgesic, antiallergic, corticosteroid, retinoid and
antiproliferative medications and mixtures thereof at any
proportion. The concentration of drugs may be adopted to exert a
therapeutic effect on a disease when applied to an afflicted
area.
[0227] Antibacterial Agents
[0228] One important class of drugs comprises antibacterial agents.
It is well known that bacterial infections are involved in a
variety of superficial disorders of the skin, eye, mucosal
membrane, oral cavity, vagina and rectum. The antibacterial drug
can be active against gram positive and gram-negative bacteria,
protozoa, aerobic bacteria and unaerobic ones.
[0229] By way of example, the antibacterial drugs can be selected
from the group of chloramphenicol, tetracyclines, synthetic and
semi-synthesic penicillins, beta-lactames, quinolones,
fluoroquinolnes, macrolide antibiotics, metronidazlole and its
derivatives and analogs, dicarboxylic acids, such as azelaic acid,
slicylates, peptide antibiotics, cyclosporines and any combination
thereof at a therapeutically effective concentration. Another group
of antibacterial agents which is non-specific, comprises strong
oxidants and free radical liberating compounds, such as hydrogen
peroxide, bleaching agents (e.g., sodium, calcium or magnesium
hypochloride and the like) iodine, chlorohexidine and benzoyl
peroxide.
[0230] Antibacterial compositions according to the present
invention may be used to treat infections of the skin. An example
of a very common skin infection is acne, which involve infestation
of the sebaceous gland with p. acnes, as well staphylococus aurus
and pseudomonas. Various antibacterial agents have been utilized to
treat acne, however, their efficacy is limited due to their low
penetration into the hydrophobic environment of the skin layers and
sebaceous glands. The composition of the present invention,
comprising a hydrophobic component, would facilitate an enhanced
rate of penetration. Furthermore, the intrinsic antibacterial and
antiinflammatory effects of the foam adjuvant agents, i.e., fatty
alcohols and acids, provides a combined effect that should result
in a better therapeutic response to treatment.
[0231] The composition of the present invention is particularly
useful and beneficial in the prevention and treatment of secondary
infections, accompanying skin-structure damage, such as in cuts,
wounds, burns and ulcers. In all such cases, the present
formulation is easy to use, being in foam state when applied and
becoming liquid instantly upon rubbing onto the skin.
[0232] While being useful in the prevention and treatment of
infections, the antibacterial foam of the present invention is also
applicable for decontaminating areas, afflicted with bacterial
warfare organisms, such as anthrax and smallpox.
[0233] The same advantage is expected when the composition of the
present invention is topically applied to mucosal membranes, the
oral cavity, the vagina and the rectum.
[0234] Anti-fungal Agents
[0235] Fungal infections are another object of treatment using the
composition of the present invention. Superficial fungal infection
of the skin is one of the commonest skin diseases seen in general
practice. Dermatophytosis is probably the most common superficial
fungal infection of the skin. It is caused by a group of fungi,
which are capable of metabolizing the keratin of human epidermis,
nails or hair. There are 3 genera of dermatophytes causing
dermatophytosis, i.e, microsporum, trichophyton and
epidermophyton.
[0236] Candidiasis is an infection caused by the yeast like fungus
candida albicans or occasionally other species of candida. Clinical
syndromes of candidiasis include: (a) oral candidiasis (oral
thrush); (b) candidiasis of the skin and genital mucous membrane;
and (c) candida paronychia, which inflicts the nail.
[0237] The pharmaceutical composition may comprise an antifungal
drug, which is active against dermatophytes and candida, selected
from the group of, but not limited to azoles, diazoles, triazoles,
miconazole, fluconazole, ketoconazole, clotrimazole, itraconazole
griseofulvin, ciclopirox, amorolfine, terbinafine, Amphotericin B,
potassium iodide, flucytosine (5FC) and any combination thereof at
a therapeutically effective concentration.
[0238] It is useful, for example for the treatment of tinea
corporis, tinea pedis, tinea rubrum, tinea unguium, tinea cruris,
tinea barbae and tinea versicolor, as well as yeast Infections,
such as candidiasis, and candidal vaginitis
[0239] Anti-viral Agents
[0240] The composition of the present invention is particularly
beneficial in the case of viral infections. Cold sores are caused
by the herpes simplex Type 1 virus and are sometimes referred to as
facial herpes. Mollusca are small viral growths that appear singly
or in groups on the face, trunk, lower abdomen, pelvis, inner
thighs, or penis. Shingles (herpes zoster), which usually only
occurs once in a lifetime, appears as a rash (clusters of blisters
with a red base). It is caused by the same virus responsible for
chickenpox. Warts are a common, benign skin tumor caused by viral
infection.
[0241] Viral infections are currently treated with various
antiviral agents, as summarized in the following table:
TABLE-US-00001 Chemical Drug Viruses Type Vidarabine Herpesviruses
Nucleoside analogue Acyclovir Herpes simplex Nucleoside (HSV)
analogue Gancyclovir Cytomegalovirus Nucleoside (CMV) analogue
Nucleoside-analog reverse Retroviruses (HIV) Nucleoside
transcriptase inhibitors (NRTI): analogue AZT (Zidovudine), ddl
(Didanosine), ddC (Zalcitabine), d4T (Stavudine), 3TC (Lamivudine)
Non-nucleoside reverse transcriptase Retroviruses (HIV) Nucleoside
inhibitors (NNRTI): Nevirapine, analogue Delavirdine Protease
Inhibitors: Saquinavir, HIV Peptide Ritonavir, Indinavir,
Nelfinavir analogue Ribavirin Broad spectrum: Triazole HCV, HSV,
carboxamide measles, mumps, Lassa fever Amantadine/Rimantadine
Influenza A strains Tricyclic amine Interferons Hepatitis B and C
Protein
[0242] Any of the above antiviral drugs, in a therapeutically
effective concentration, can be incorporated in the foam
composition of the present invention. The composition of the
present invention, which comprises a hydrophobic solvent, would
facilitate an enhanced rate of penetration and better topical
distribution of any of the above listed antiviral drugs.
Furthermore, the intrinsic antiviral effects of the foam adjuvant
agents, i.e., fatty alcohols and acids, provides a combined effect
that should result in a better therapeutic response to
treatment.
[0243] Antiinflammatory or Antiallergic Agents
[0244] Yet, according to another embodiment according to the
present invention the drug is an antiinflammatory or antiallergic
agent. Antiinflammatory or antiallergic agent can be selected from
the group of corticosteroids, non-steroidal antiinflammatory drugs
(NSAIDs), anti-histamines, immunosuppressants and any combination
thereof at a therapeutically effective concentration.
[0245] The following table provides a summary of currently
available corticosteroid agent and their typical therapeutically
effective concentration. TABLE-US-00002 Potency Compound
Formulation Very high Clobetasol proprionate Cream or ointment
0.05% Halobetasol proprionate Cream or ointment 0.05% High
Betamethasone diproprionate Cream or ointment 0.05% Betamethasone
valerate Ointment 0.1% Fluocinolone acetonide Cream 0.02%
Halcinonide Cream or ointment 0.1% Medium Betamethasone valerate
Cream 0.1% Fluocinolone acetonide Cream or ointment 0.020%
Hydrocortisone valerate Cream or ointment 0.2% Triamcinolone
acetonide Cream, ointment, or lotion 0.1% or 0.020% Low
Hydrocortisone Cream, ointment, or lotion 1.0% or 2.5%
[0246] The concentrations of corticosteroid drugs, as presented in
the above table are provided herein only as example, and any
therapeutically effective concentration of such corticosteroids can
be incorporated in the composition of the present invention.
[0247] Since all corticosteroid drugs are typically hydrophobic,
the carrier of the present invention, comprising a hydrophobic
solvent, is most suitable as a vehicle to facilitate better topical
distribution and an enhanced rate of penetration of any of the
above listed drugs. Furthermore, the intrinsic antiviral,
antibacterial and antiinflammatory effects of the foam adjuvant
agents, i.e., fatty alcohols and acids, provides a combined effect
that should result in a better therapeutic response to
treatment.
[0248] Psoriasis is a very common chronic skin disease, which may
be the target of treatment using the composition of the present
invention. It is marked by periodic flare-ups of sharply defined
red patches covered by a silvery, flaky surface.
[0249] Corticosteroid ointments, greasy preparations containing
little or no water, are commonly used for treating psoriasis. Their
main disadvantage is in their sticky feeling, which remains so long
after treatment is over. By contrast, the foam of the present
invention, while comprising considerable concentration of an oil
(hydrophobic solvent), spreads very easily throughout the afflicted
area and absorbs into the skin without leaving any untoward
sensation or look. Examples of other inflammatory disorders, which
can be treated by the composition of the present invention, wherein
the drug is a steroid are atopic dermatitis, seborrhea, seborrheic
dermatitis of the face and trunk, seborrheic blepharitis, contact
dermatitis, stasis dermatitis (gravitational eczema; varicose
eczema), exfoliative dermatitis (erythroderma), lichen simplex
chronicus, pityriasis rosea and pemphigus.
[0250] Topical antihistaminic preparations currently available
include 1% and 2% diphenhydramine (Benadryl.RTM. and
Caladryl.RTM.), 5% doxepin (Zonalon.RTM.) cream, phrilamine
maleate, chlorpheniramine and tripelennamine, phenothiazines,
promethazine hydrochloride (Phenergan.RTM.) and dimethindene
maleate. These drugs, as well as additional antihistamins can also
be incorporated in the composition of the present invention.
[0251] It is pointed out that polyunsaturated fatty acids,
containing omega-3 and omega-6 fatty acids (e.g., linoleic and
linolenic acid, gamma-linoleic acid (GLA), eicosapentaenoic acid
(EPA) and docosahexaenoic acid (DHA) are beneficial in the
treatment of psoriasis and other skin inflammation conditions.
[0252] A second class of anti-inflammatory agents, which is useful
in the foam of the present invention, includes the nonsteroidal
anti-inflammatory agents (NSAIDs). The variety of compounds
encompassed by this group is well-known to those skilled in the
art. Specific non-steroidal anti-inflammatory agents useful in the
composition invention include, but are not limited to:
[0253] 1) Oxicams, such as piroxicam, isoxicam, tenoxicam,
sudoxicam;
[0254] 2) Salicylates, such as salicylic acid, ethyl salicylate,
methyl salycilate, aspirin, disalcid, benorylate, trilisate,
safapryn, solprin, diflunisal, and fendosal;
[0255] 3) Acetic acid derivatives, such as diclofenac, fenclofenac,
indomethacin, sulindac, tolmetin, isoxepac, furofenac, tiopinac,
zidometacin, acematacin, fentiazac, zomepirac, clindanac, oxepinac,
felbinac, and ketorolac;
[0256] 4) Fenamates, such as mefenamic, meclofenamic, flufenamic,
niflumic, and tolfenamic acids;
[0257] 5) Propionic acid derivatives, such as ibuprofen, naproxen,
benoxaprofen, flurbiprofen, ketoprofen, fenoprofen, fenbufen,
indopropfen, pirprofen, carprofen, oxaprozin, pranoprofen,
miroprofen, tioxaprofen, suprofen, alminoprofen, and tiaprofenic;
and
[0258] 6) Pyrazoles, such as phenylbutazone, oxyphenbutazone,
feprazone, azapropazone, and trimethazone.
[0259] Any further steroidal and nonsteroidal compounds, having the
capacity to prevent, alleviate the symptoms of, treat or cure
inflammation processes, are generally included, as possible
anti-inflammatory agents, according to the present invention.
[0260] The pharmaceutical composition of the present invention may
also comprise an antiinflammatory or antiallergic agent, wherein
said agent reduces the occurrence of pro-inflammatory cytokines or
inhibits the effect of pro-inflammatory cytokines.
[0261] Mixtures of such anti-inflammatory agents may also be
employed, as well as the dermatologically acceptable salts, esters,
amides, prodrugs and derivatives of these agents.
[0262] Topical application of a foam, comprising a safe and
effective dose of an NSAID can be useful in the prevention and/or
alleviation of the symptoms of rheumatoid arthritis, osteoarthritis
and pain. Topical NSAIDs, incorporated in the foam of the present
invention can be also used in the treatment of dermatological
disorders, such as acne, rosacea, hair growth disorders, actinic
keratosis and certain skin cancer conditions.
[0263] Topical Anesthetics
[0264] The compositions of the present invention may contain a safe
and effective amount of a topical anesthetic. Examples of topical
anesthetic drugs include benzocaine, lidocaine, bupivacaine,
chlorprocaine, dibucaine, etidocaine, mepivacaine, tetracaine,
dyclonine, hexylcaine, procaine, cocaine, ketamine, pramoxine,
phenol, and pharmaceutically acceptable salts thereof. Mixtures of
such anesthetic agents may be synergistically beneficial.
[0265] Keratolytically Active Agents The term "keratolytically
active agent" is used herein to mean a compound which loosens and
removes the stratum corneum of the skin, or alters the structure of
the keratin layers of skin.
[0266] Keratolytically active agents are used in the treatment of
many dermatological disorders, which involve dry skin,
hyperkeratiinization (such as prsoriasis), skin itching (such as
xerosis), acne and rosacea.
[0267] Suitable keratolytically active agent include phenol and
substituted phenolic compounds. Such compounds are known to
dissolve and loosen the intracellular matrix of the
hyperkeratinized tissue. As such, they are used in the treatment of
dermatological disorders. Dihydroxy benzene and derivatives thereof
have been recognized as potent keratolytic agents. Resorcinol
(m-dihydroxybenzene) and derivatives thereof are used in anti-acne
preparations. Hydroquinone (p-dihydroxybenzene), besides its
anti-pigmentation properties, is also keratolytic. These compounds
also exhibit antiseptic properties. Cresols also possess
bactericidal and keratolytic properties.
[0268] Vitamin A and its derivatives, such as retinoic acid,
isoretinoic acid, retinol and retinal are another preferred class
of keratolytically active agents.
[0269] Another group of keratolytically active agents include
alpha-hydroxy acids, such as lactic acid and glycolic acid and
their respective salts and derivatives; and beta-hydroxy acids,
such as Salicylic acid (o-hydroxybenzoic acid) and its salts and
pharmaceutically acceptable derivatives, which typically possess
antiinflammatory, as well as keratolytic, activity.
[0270] Yet, another class of preferred keratolytically active
agents includes urea and its derivatives.
[0271] Retinoids Another preferred group of active agents comprise
retinol, retinal, all trans retinoic acid and derivatives, isomers
and analogs thereof, collectively termed "retinoids". Etretinate,
actiretin, isotretinoin, adapalene and tazarotene are further
examples of said retinoid isomers and analogs. Compositions
according to the present invention, which contain retinoids as the
active drug, can be used for the treatment of acne, seborrhea,
various dermatoses, inflammation of the skin, mucosal membranes,
vagina and the rectum, psoriasis, actinic keratosis and skin
cancers, by application onto the affected area.
[0272] Insecticide and Insect Repellents Agents
[0273] Insects, such as mosquitoes, biting flies, mites, gnats,
fleas, chiggers, punkies, sand flies, lice and ticks can be
annoying and sometimes pose a serious risk to human and animal
health. In certain areas of the United States, mosquitoes can
transmit diseases like equine and St. Louis encephalitis. Biting
flies can inflict a painful bite that can persist for days, swell,
and become infected. Ticks can transmit serious diseases like Lyme
disease and Rocky Mountain spotted fever.
[0274] There are several types of insect repellents to use when
protecting people and animals from flying or biting insects,
spiders, ticks and mites. By way of example, these may include DEET
(N, N-diethyl-m-toluamide), dimethyl phthalate, piperonyl butoxide
and permethrin. Insect repelling terpenoids, have been reported by
Hwang, et al, J. Chem. Ecol., 11, 1297 (1-985); and Ruledge, J. Am.
Mosquito Control Assoc. 4, 414 (1988).
[0275] A particularly preferred group of insect repellents includes
the terpenoid compounds, described in U.S. Pat. No. 5,411,992,
including:
[0276] (1) Terpenoid-alcohol or terpene-ols are terpenoids which
have at least one hydroxyl group. Examples of terpene-ols include:
C.sub.10H.sub.16O compounds, perillyl alcohol, carveol, myrtenol,
and cis-verbenol; C.sub.10H.sub.18O compounds, myrtanol,
iso-pinocampheol, dihydrocarveol, isopulegol, terpineol,
terpinen-4-ol, nerol, geraniol, and linalool, and C.sub.10H.sub.20O
compounds, menthol, beta-citronellol, and dihydro-myrcenol.
[0277] (2) Terpenoid-esters are terpenoids, which have at least one
ester group which is the product of the bonding of the hydroxyl
group of a terpene-ol with an aliphatic carboxylic acid that can
contain functional groups such as the hydroxyl or amine on the
aliphatic chain. Examples of suitable aliphatic carboxylic acids
include acetic acid, propionic acid, lactic acid, and various amino
acids.
Examples of terpenoid-esters include: carvyl acetate, carvyl
propionate, and menthyl lactate.
[0278] (3) Essential oils which contain terpenoids and perfumes
which contain terpenoids. Non-limiting examples of essential oils
which have high content of terpene-ols and esters include bergamot
(62% terpenoids); sage (>50% terpenoids); styrax (>50%
terpenoids); peppermint (>50% terpenoids); and pine Siberian
(75% terpenoids %). Terpenes, aldehydes and ketones vary in their
usefulness but as a general group have potential as
insect-repellent.
[0279] The foam of the present invention is particularly suitable
for the effective uniform spreading of an insect repellent agent
onto large areas of the skin of humans and animals. The hydrophobic
solvent present in the foam composition helps retain the insect
repellent on the skin surface for an extended period of time.
[0280] Yet, in a further embodiment, the foam is suitable for
delivery of insect-killing agents (insecticides) to an afflicted
external surface area of humans and animals. Thus, the
pharmaceutical or cosmetic composition may comprise an insecticide,
known in the art of parasitology. By way of example, such
insecticide can be selected selected from the group of permethrin,
hexachlorobenzene, carbamate, naturally occuring pyrethroids,
permethrin, allethrin, malathion, piperonyl butoxide and any
combination thereof at a therapeutically effective concentration.
Its application is very convenient and it spreads easily, even over
hairy areas. The hydrophobic solvent present in the foam
composition helps retain the insecticide on the treated area for an
extended period of time. Furthermore, the presence of a hydrophobic
solvent in the foam eases mechanical removal of lice and nits with
a comb.
[0281] Anti Cancer Drugs
[0282] Anti cancer drugs can also be used according to the present
invention as the drug of choice from skin malignant tumors, such as
basal cell carcinoma, squamous sell carcinoma, melanoma and
Kaposi's sarcoma, as well as the pre-cancerous condition actinic
keratosis. In certain cases, topical cytotoxic and
antiproliferative drugs are used to treat or prevent such cancers,
including 5-fluorouracil, also called 5-FU. 5-FU, as well as any
other anti-cancer agents, know in the art of cancer medicine, can
be incorporated in the foam at therapeutically effective
levels.
[0283] A preferred family of anticancer drugs, suitable for usage
in the foam of the present formulation comprises antiestrogens,
such as tamoxifen. Tamoxifen blocks the effects of the hormone
estrogen in the body. It is used to prevent or delay the return of
breast cancer or to control its spread.
[0284] Photodynamic Therapy Agents
[0285] The foam composition of the present invention is also useful
to deliver photo-sensitizing agents, known in the art of
photodynamic therapy. By way of example, such photosensitizers can
be selected from the group comprising modified porphyrins,
chlorins, bacteriochlorins, phthalocyanines, naphthalocyanines,
pheophorbides, purpurins, m-THPC, mono-L-aspartyl chlorin e6,
bacteriochlorins, phthalocyanines, benzoporphyrin derivatives, as
well as photosensitiser precursors, such as aminolevulinic acid
(ALA).
[0286] Active Agents for Burns, Wounds, Cuts and Ulcers
[0287] The treatment of burns, wounds, cuts and ulcers, using the
composition of the present invention is particularly advantageous.
The foam can include both anti-infective agents (against bacteria,
fungi and/or viruses), antiinflammatory agents (steroidal and/or
NSAIDs) and pain relieving components. Upon application, the foam
spreads easily, covering the surface of the affected area, and
without causing pain.
SKIN CARE ACTIVE AGENTS
[0288] The foam of the present invention is useful and advantageous
for skin care and cosmetic care. The combination of oil and water,
having moisture-retaining properties, in a spreadable foam form,
can be used to substitute currently used cosmetic skin care creams,
lotions, gels, etc. The cosmetic foam compositions of the present
invention are suitable for the further application as
"cosmeceutical" preparation (cosmetic products with therapeutic
benefit), to treat "cosmetic" skin disorders, such as aging skin,
wrinkles, hyperpigmentation (melasma, chloasma, freckles, etc.),
scaly skin and other skin undesirable properties.
[0289] The CTFA Cosmetic Ingredient Handbook describes a wide
variety of nonlimiting cosmetic and pharmaceutical ingredients
commonly used in the skin care industry, which are suitable for use
in the compositions of the present invention. Examples of these
ingredient classes include: abrasives, absorbents, aesthetic
components such as fragrances, pigments, colorings/colorants,
essential oils, astringents, etc. (e.g., clove oil, menthol,
camphor, eucalyptus oil, eugenol, menthyl lactate, witch hazel
distillate), anti-acne agents, antimicrobial agents (e.g.,
iodopropyl butylcarbamate), antioxidants, binders, biological
additives, buffering agents, bulking agents, chelating agents,
chemical additives, colorants, cosmetic astringents, cosmetic
biocides, denaturants, drug astringents, external analgesics, film
formers or materials, e.g., polymers, for aiding the film-forming
properties and substantivity of the composition (e.g., copolymer of
eicosene and vinyl pyrrolidone), opacifying agents, pH adjusters,
propellants, reducing agents, sequestrants, skin bleaching and
lightening agents (e.g., hydroquinone, kojic acid, ascorbic acid,
magnesium ascorbyl phosphate, ascorbyl glucosamine),
skin-conditioning agents (e.g., humectants, including miscellaneous
and occlusive), skin soothing and/or healing agents (e.g.,
panthenol and derivatives (e.g., ethyl panthenol), aloe vera,
pantothenic acid and its derivatives, allantoin, bisabolol, and
dipotassium glycyrrhizinate), skin treating agents, thickeners, and
vitamins and derivatives thereof.
[0290] In any embodiment of the present invention, however, the
active agents useful herein can be categorized by the benefit they
provide or by their postulated mode of action. It is to be
understood that the active agents useful herein can in some
instances provide more than one benefit or operate via more than
one mode of action. Therefore, classifications herein are made for
the sake of convenience and are not intended to limit the active to
that particular application or applications listed.
[0291] Anti-acne Active Agents
[0292] The compositions of the present invention may contain a safe
and effective amount of one or more pharmaceutically or
cosmetically acceptable anti-acne active agents. Examples of useful
anti-acne actives include resorcinol, sulfur, salicylic acid and
salicylates, alpha-hydroxy acids, nonsteroidal anti-inflammatory
agents, benzoyl peroxide, retinoic acid, isoretinoic acid and other
retinoid compounds, adapalene, tazarotene, azelaic acid and azelaic
acid derivatives, antibiotic agents, such as erythromycin and
clyndamycin, zinc salts and complexes, and combinations thereof, in
a therapeutically effective concentration.
[0293] Anti-wrinkle Active Agents/anti-atrophy Active Agents and
Agents to Treat Dry and Scaly Skin (Xerosis and Ichthyosis)
[0294] The compositions of the present invention may further
contain a safe and effective amount of one or more anti-wrinkle
actives or anti-atrophy actives, which can be easily delivered by
spreading a foam onto the skin. Exemplary anti-wrinkle/anti-atrophy
active agents suitable for use in the compositions of the present
invention include sulfur-containing D and L amino acids and their
derivatives and salts, particularly the N-acetyl derivatives;
thiols; hydroxy acids (e.g., alpha-hydroxy acids such as lactic
acid and glycolic acid and their derivatives and salts; or
beta-hydroxy acids such as salicylic acid and salicylic acid salts
and derivatives), urea, hyaluronic acid, phytic acid, lipoic acid;
lysophosphatidic acid, skin peel agents (e.g., phenol, resorcinol
and the like), vitamin B3 compounds (e.g., niacinamide, nicotinic
acid and nicotinic acid salts and esters, including
non-vasodilating esters of nicotinic acid (such as tocopheryl
nicotinate), nicotinyl amino acids, nicotinyl alcohol esters of
carboxylic acids, nicotinic acid N-oxide and niacinamide N-oxide),
vitamin B5 and retinoids (e.g., retinol, retinal, retinoic acid,
retinyl acetate, retinyl palmitate, retinyl ascorbate). In the case
of dry, scaly skin (xerosis) and ichthyosis such agents can
alleviate the symptoms by temporary relief of itching associated
with these conditions.
[0295] Anti-oxidants/radical Scavengers
[0296] A safe and effective amount of an anti-oxidant/radical
scavenger may be added to the compositions of the subject
invention, preferably from about 0.1% to about 10% (w/w), more
preferably from about 1% to about 5% (w/w), of the composition.
[0297] Anti-oxidants/radical scavengers such as ascorbic acid
(vitamin C) and its salts, ascorbyl esters of fatty acids, ascorbic
acid derivatives (e.g., magnesium ascorbyl phosphate, sodium
ascorbyl phosphate, ascorbyl sorbate), tocopherol (vitamin E),
tocopherol sorbate, tocopherol acetate, other esters of tocopherol,
butylated hydroxy benzoic acids and their salts,
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid
(commercially available under the tradename Trolox.sup.R), gallic
acid and its alkyl esters, especially propyl gallate, uric acid and
its salts and alkyl esters, sorbic acid and its salts, lipoic acid,
amines (e.g., N,N-diethylhydroxylamine, amino-guanidine),
sulfhydryl compounds (e.g., glutathione), dihydroxy fumaric acid
and its salts, lycine pidolate, arginine pilolate,
nordihydroguaiaretic acid, bioflavonoids, curcumin, lysine,
methionine, proline, superoxide dismutase, silymarin, tea extracts,
grape skin/seed extracts, melanin, and rosemary extracts may be
used.
[0298] The foam of the present invention is suitable for delivering
skin protecting and revitalizing anti-oxidants/radical scavengers.
It is further pointed out that polyunsaturated fatty acids,
containing omega-3 and omega-6 fatty acids (e.g., linoleic and
linolenic acid, gamma-linoleic acid (GLA), eicosapentaenoic acid
(EPA) and docosahexaenoic acid (DHA) are beneficial in the
treatment of psoriasis and other skin inflammation conditions.
Likewise, emollients and silicone oils exert moisture-retaining and
skin protective effects on the skin. Thus in a preferred
embodiment, a skin protective foam is provided, wherein the
hydrophobic solvent comprises in full or in part, a solvent,
selected from the group of emollients, silicone oil and oils, rich
in unsaturated fatty acids, thus, affording a synergistic
therapeutic effect of the anti-oxidants/radical scavenger agent and
the vehicle components.
[0299] Self-tanning Active Agents
[0300] The foam of the present invention is particularly suitable
for the uniform delivery of a tanning active agent onto large areas
of the skin. It is preferable that the compositions contain from
about 0.1% to about 20%, more preferably from about 2% to about 7%,
and still more preferably from about 3% to about 6%, of the
composition, of dihydroxyacetone, or any other compound, know in
the art as an artificial tanning active agent.
[0301] Skin Lightening and Whitening Agents
[0302] The foam of the present invention is particularly suitable
for the uniform delivery of a skin lightening agent. When used, the
compositions preferably contain from about 0.1% to about 10%, more
preferably from about 0.2% to about 5%, of the composition, of a
skin-lightening agent. Suitable skin lightening or whitening agents
include those known in the art, including hydroquinone, azelaic
acid and other related dicarboxylic acids, and salts and
derivatives thereof, retinoids, kojic acid, arbutin, nicotinic acid
and its precursors, salts and derivatives, arbutin, ascorbic acid
and salts and derivatives thereof (e.g., magnesium ascorbyl
phosphate or sodium ascorbyl phosphate), and herbal extracts (e.g.,
licorice extract, mulberry extract, placental extract).
[0303] In one or more embodiments of the present invention, the
foam composition comprises a combination of a skin whitening agent
and a sunscreen agent.
[0304] In one or more embodiments of the present invention, the
foam composition comprises a combination of a skin whitening agent
and an inorganic sunscreen agent. When inorganic sunscreen agents,
e.g. TiO.sub.2, are rubbed onto the skin, they leave a white
coating, which provides an immediate (although transient) whitening
effect, which is highly desirable by the consumer, who wishes to
see instant change in his/her appearance. The whitening agent, in
combination with the inorganic sunscreen agent in the foam carrier
can be easily and uniformly distributed on the skin surface,
thereby affording an even instant whitening effect, unlike creams
that are difficult to spread evenly on skin areas.
[0305] Sunscreens
[0306] Exposure to ultraviolet light can result in excessive
scaling and texture changes of the stratum corneum. The foam of the
present invention is advantageous for the delivery of sunscreen
agents. Its application is very convenient and it spreads easily
over large skin areas. The presence of a hydrophobic solvent in the
foam ensures long lasting effect, even while bathing.
[0307] As used herein, "sunscreen active" or "sunscreen agent"
includes both sunscreen agents and physical sunblocks. Suitable
sunscreen actives may be organic or inorganic.
[0308] Inorganic sunscreens useful herein include the following
metallic oxides; titanium dioxide having an average primary
particle size of from about 15 nm to about 100 nm, zinc oxide
having an average primary particle size of from about 15 nm to
about 150 nm, zirconium oxide having an average primary particle
size of from about 15 nm to about 150 nm, iron oxide having an
average primary particle size of from about 15 nm to about 500 nm,
and mixtures thereof. When used herein, the inorganic sunscreens
are present in the amount of from about 0.1% to about 20%,
preferably from about 0.5% to about 10%, more preferably from about
1% to about 5%, of the composition.
[0309] A wide variety of conventional organic sunscreen actives are
suitable for use herein. Specific suitable sunscreen actives
include, for example: p-aminobenzoic acid, its salts and its
derivatives (ethyl, isobutyl, glyceryl esters;
p-dimethylaminobenzoic acid); anthranilates (i.e.,
o-amino-benzoates; methyl, menthyl, phenyl, benzyl, phenylethyl,
linalyl, terpinyl, and cyclohexenyl esters);
[0310] salicylates (amyl, phenyl, octyl, benzyl, menthyl, glyceryl,
and di-pro-pyleneglycol esters); cinnamic acid derivatives (menthyl
and benzyl esters, a-phenyl cinnamonitrile; butyl cinnamoyl
pyruvate); dihydroxycinnamic acid derivatives (umbelliferone,
methylumbelliferone, methylaceto-umbelliferone);
trihydroxy-cinnamic acid derivatives (esculetin, methylesculetin,
daphnetin, and the glucosides, esculin and daphnin); hydrocarbons
(diphenylbutadiene, stilbene);
[0311] dibenzalacetone and benzalacetophenone; naphtholsulfonates
(sodium salts of 2-naphthol-3,6-disulfonic and of
2-naphthol-6,8-disulfonic acids); di-hydroxynaphthoic acid and its
salts; o- and p-hydroxybiphenyldisulfonates;
[0312] coumarin derivatives (7-hydroxy, 7-methyl, 3-phenyl);
diazoles (2-acetyl-3-bromoindazole, phenyl benzoxazole, methyl
naphthoxazole, various aryl benzothiazoles); quinine salts
(bisulfate, sulfate, chloride, oleate, and tannate);
[0313] quinoline derivatives (8-hydroxyquinoline salts,
2-phenylquinoline); hydroxy- or methoxy-substituted benzophenones;
uric and violuric acids; tannic acid and its derivatives (e.g.,
hexaethylether); (butyl carbotol) (6-propyl piperonyl) ether;
[0314] hydroquinone; benzophenones (oxybenzene, sulisobenzone,
dioxybenzone, benzoresorcinol, 2,2', 4,4'-tetrahydroxybenzophenone,
2,2'-dihydroxy-4,4'-dimethoxybenzophenone, octabenzone;
4-isopropyldibenzoylmethane; butylmethoxydibenzoylmethane;
etocrylene; octocrylene; [3-(4'-methylbenzylidene bornan-2-one),
terephthalylidene dicamphor sulfonic acid and
4-isopropyl-di-benzoylmethane.
[0315] A safe and effective amount of the organic sunscreen active
is used, typically from about 1% to about 20%, more typically from
about 2% to about 10% of the composition. Exact amounts will vary
depending upon the sunscreen or sunscreens chosen and the desired
Sun Protection Factor (SPF).
[0316] Agents for Hair Growth Disorders
[0317] Agents, which affect the pattern of hair growth, can be
suitably incorporated in the foam of the present invention. Male
patterrn baldness (MPB), the commonest cause of balding, is induced
by the activity of the male hormone dihydrotestosterone (DHT),
which converted from the hormone testosterone by the enzymes 5
alpha reductase. Current treatments of MPB include minoxidil and
agents, which inhibit 5 alpha reductase, such as finasteride,
spironolactone, azelaic acid and azelaic acid derivatives and
salts. Such agents, as well as other agents known in the art, can
be incorporated in the foam of the present invention.
[0318] It is further pointed out that polyunsaturated fatty acids,
i.e., such which include any of the essential fatty acids (EFA's):
linoleic and linolenic acid, gamma-linoleic acid (GLA),
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are
also known to contribute to hair growth. Thus in a preferred
embodiment, a hair growth foam is provided, wherein the hydrophobic
solvent comprises in full or in part, an oil, rich in such
unsaturated fatty acids.
[0319] Figure-forming Agents; Agents to Treat
Cellulite/Slimming
[0320] Figure forming agents such as used in the treatment of
cellulite and in slimming products, can be suitably incorporated in
the foam of the present invention. A non-limiting exemplary list of
active agents, known in the treatment of cellulite and in the
induction of a slimming effect include herbal extracts, such as
baldderwack extract, butcher's, broom, cayenne, dandelion, red
clover, ginkgo biloba, horse chestnut, witch hazel and borage oil,
omega 3 and omega 6 oils, caffeic acid and salts and derivatives
thereof, xanthine agents, such as caffeine, theophiline and
pentoxyphilline, and nicotinic acid and salts and derivatives
thereof.
[0321] Agents to Treat Sunburn, Heat Burn, Radiation Burn, Rash and
Itch
[0322] Cosmetic and pharmaceutical ingredients which are known in
the art of pharmacology and cosmetology to treat dermatitis, minor
skin irritations, sunburn, heat burn, radiation burn, and inhibit
inflammation can be beneficially incorporated in the foam of the
present invention.
[0323] Examples of such active agents include chamomile extract
(matricaria recutitia), cucumber distillate (cucumis sativus),
lavender water (lavendula angustifolia), rose water (rosa
damascena), witch hazel (hamamelis virginiana), allantoin,
bisabolol, rosehip oil, calendula oil, azulaene, menthol and
camphor.
[0324] Use of the Foam as a Lubricating and Protective Foam
[0325] There are several potential uses of the foam, particularly
the silicone-oil based foam, as a lubricating foam. Typical
examples are shaving foam, moisture protection foam and
antifriction foam. For such purposes, the foam can be used in its
basic composition (without additional formulation aids and active
ingredients), or with the addition of such additives.
FOAM FOR NEUTRALIZATION AND/OR DECONTAMINATION OF HAZARDOUS
CHEMICALS AND TREATMENT OF HEAT BURNS
[0326] It has been reported that povidone iodine antiseptic, a
popular iodine product, can ameliorate damage to guinea pig skin
exposed to mustard gas and other chemical irritants and further
reduces, and many times prevents, damage to human skin after
accidental heat burns caused by hot water, oil or hot steam.
[0327] Other active compound, having decontamination abilities,
comprise strong oxidants and free radical liberating compounds,
such as hydrogen oxide, bleaching agents (e.g., sodium, calcium or
magnesium hypochloride and the like) iodine, chlorohexidine and
benzoyl peroxide.
[0328] The alcohol-free foam of the present invention, comprising
one or more of the above decontaminating and neutralizing agents
can be applied onto the contaminated skin to form a preventive
layer, prior to contamination measure or as a
decontamination/neutralization means, right after contamination has
occurred.
PENETRATION ENHANCERS
[0329] A penetration enhancer or permeation enhancer is an agent
used to increase the permeability of the skin to a
pharmacologically active agent to increase the rate at which the
drug diffuses through the skin and enters the tissues and
bloodstream. A chemical skin penetration enhancer increases skin
permeability by reversibly altering the physiochemical nature of
the stratum corneum to reduce its diffusional resistance. In a
review of the technical and patent literature up to 1996, numerous
chemical compounds were cited as skin penetration enhancers. Most
of the compounds are generally recognized as safe (GRAS)
ingredients that would often be considered inert by a formulator
(Osborne D W, Henke J J, Pharmaceutical Technology, November 1997,
pp 58-86.)
[0330] Examples of penetration enhancers, according to the present
invention include: polyols, such as propylene glycol, hexylene
glycol, diethylene glycol, propylene glycol n-alkanols, terpenes,
di-terpenes, tri-terpenes, terpen-ols, limonene, terpene-ol,
1-menthol, dioxolane, ethylene glycol, other glycols, and glycerol;
sulfoxides, such as dimethylsulfoxide (DMSO), dimethylformanide,
methyl dodecyl sulfoxide, dimethylacetamide; monooleate of
ethoxylated glycerides (with 8 to 10 ethylene oxide units); Azone
(1 -dodecylazacycloheptan-2-one), 2-(n-nonyl)-1,3-dioxolane;
esters, such as isopropyl myristate/palmitate, ethyl acetate, butyl
acetate, methyl proprionate, capric/caprylic triglycerides,
octylmyristate, dodecyl-myristate; myristyl alcohol, lauryl
alcohol, lauric acid, lauryl lactate ketones; amides, such as
acetamide oleates such as triolein; various surfactants, such as
sodium lauryl sulfate; various alkanoic acids such as caprylic
acid; lactam compounds, such as azone; alkanols, such as oleyl
alcohol; dialkylamino acetates, and admixtures thereof.
[0331] Lower alcohols, such as ethanol, propanol, isopropanol,
butanol, iso-butanol, t-butanol and pentanol are not considered
appropriate penentartion enhancers according to the present
invention, due to their skin drying and irritation properties.
[0332] Yet, another preferred class of penetration enhancers in the
cyclodextrines and related compounds. Cyclodextrins are
structurally related cyclic oligomaltoses which form a new group of
pharmaceutical excipients. These are torus-shaped molecules with a
hydrophilic outer surface and a lipophilic central cavity.
Cyclodextrins are capable of forming water-soluble inclusion
complexes with a wide variety of lipophilic water-insoluble drugs
by taking up a whole drug molecule, or some part of it, into the
cavity. The cyclodextrin molecules are relatively large (molecular
weight ranging from almost 1000 to over 1500), with a hydrated
outer surface, and under normal conditions, cyclodextrin molecules
will only permeate the skin barrier with considerable difficulty.
It is generally believed that the cyclodextrin molecules act as
true carriers by keeping lipophilic drug molecules in solution and
deliver them to the skin surface where they partition from the
cyclodextrin cavity into the skin.
FURTHER TECHNICAL PARAMETERS
[0333] The composition of the present invention may be contained in
and dispensed from a container capable of withstanding the pressure
of the propellant gas and having an appropriate valve/nozzle for
dispensing the composition as foam under pressure. A customary
liquefied or compressed gas propellant can be added, in the amount
of about 5-25% of the total composition. Liquefied propellants are
gases that exist as liquids under pressure, including high purity
hydrocarbons such as propane, isobutane and n-butane, dimethyl
ether and chlorofluorocarbons (CFCs). Compressed gasses are
exemplified by air, nitrogen and carbon dioxide.
[0334] A specific embodiment according to the present invention
comprises placing the composition of the present invention on a
patch, occlusive tape or the skin-contact compartment of a
transdermal delivery apparatus and applying such object onto the
skin, in order to attain effective superficial treatment or
enhanced penetration of the drug into the skin or through the
skin.
[0335] Utilizing such strategy, one can apply drugs, which are
currently administered systemically or that require transdermal
delivery, in the preferred therapeutic system of the present
invention. Examples for such drugs are nicotine, testosterone and
other male hormones and male hormone precursors, estrogen and other
female hormones and hormone precursors, growth hormone, insulin,
caffeine, steroidal and non-steroidal antiinflammatory agents and
thyroid hormone substitutes.
[0336] The general process, as typically exemplified in Example 1
may be applied in order to produce the composition of the present
invention. The pharmaceutical carrier according to the present
invention can also be used to prepare cosmetics for beauty purpose
by adding into skin care agents and perfume.
EXAMPLES
[0337] The invention is described with reference to the following
examples. This invention is not limited to these examples and
experiments. Many variations will suggest themselves and are within
the full intended scope of the appended claims.
Example 1
General Procedure for Preparing Foamable Composition
[0338] Aqueous Phase: Water gelling agent and surface-active agent
are dissolved in water, with agitation. The solution is warmed to
50-70.degree. C. Water soluble cosmetic or pharmaceutical active
ingredients and optional water soluble ingredients are added with
agitation to the Aqueous Phase mixture.
[0339] Hydrophobic Phase: The hydrophobic solvent is heated to same
temperature. Foam adjuvant agent is added to preheated hydrophobic
solvent. Oil soluble cosmetic or pharmaceutical active ingredients*
and optional oil soluble formulation ingredients are added with
agitation to the Hydrophobic Phase mixture.
[0340] The warm Hydrophobic Phase is gradually poured into the warm
Aqueous Phase, with agitation, followed by Ultraturax
homogenization. The mixture is allowed to cool down to ambient
temperature. In case of heat sensitive active ingredients, the
active ingredient is added with agitation to the mixture after
cooling to ambient temperature. The mixture, at ambient
temperature, is added to an aerosol container, the container is
sealed and appropriate amount of propellant (5-25 w % of the
composition mass) is added under pressure into the container.
Example 2
Vegetable Oil-Based Foam Carrier Composition
[0341] TABLE-US-00003 Version Version Version No. 1 No. 2 No. 3
Ingredient % (W/W) Hydrophobic solvent Soybean oil 40 30.5 20 Water
Water 48.5 32.5 61 Foam adjuvant agent Stearyl Alcohol 0.8 1.05
0.73 Surface-active agent Sucrose ester SP70 0.64 0.45 0.8 Water
gelling agent Xanthan Gum 0.16 0.11 0.1 Methocel ELV15 0.32 0.22
0.28 Other Ingredients Antioxidant 0.02 0.02 0.02 Preservatives 0.3
0.3 0.3 Fragrance 0.2 0.2 0.2 Foam Specific gravity 0.10 0.15 0.065
(gr/mL)
[0342] The compositions use a non-ionic surfactant and contain a
combined amount of surface-active agent, foam adjuvant and water
gelling agent ranging from 1.83% to 1.92% (w/w). The foam of this
example is useful as a carrier of active pharmaceutical and/or
cosmetic active ingredients, as exemplified below. It also can be
used as a protective product. Additionally, it is also useful as
lubricating foam, for various purposes.
Example 3
Silicone Oil-Based Foam Carrier Composition
[0343] TABLE-US-00004 Version Version No. 1 No. 2 Specific
Ingredient % (W/W) Hydrophobic solvent Dimeticone 350* 25 10 Water
Water 72 87 Foam adjuvant agent Stearyl Alcohol 0.2 0.2
Surface-active agent Sucrose ester SP70 0.8 -- Myrj 49P -- 0.8
Water gelling agent Xanthan Gum 0.2 0.2 Methocel ELV15 0.4 0.4
Other Ingredients Antioxidant 0.02 0.02 Preservatives 1 1 Fragrance
0.2 0.2 Foam Specific gravity (gr/mL) 0.10 ND *Dimethylpolysiloxane
of 350 cps viscosity.
[0344] The compositions use only non-ionic surfactant and contain a
combined amount of surface-active agent, foam adjuvant and water
gelling agent of 1.6% (w/w). The foam of this example is useful as
a carrier of active pharmaceutical and/or cosmetic active
ingredients, as exemplified below. It also can be used as a
protective product. Additionally, it is also useful as lubricating
foam, for various purposes.
Example 6
Mineral Oil-Based Foam Carrier Composition
[0345] TABLE-US-00005 Version Version Version Version Version No. 1
No. 2 No. 3 No. 4 No. 5 Ingredient % (W/W) Hydrophobic solvent
Mineral oil 69 50 50 25 25 Water Water 28.4 46.7 46.7 71.88 71.9
Foam adjuvant Stearyl Alcohol 0.7 1 1 0.5 0.5 agent Surface-active
Sucrose ester SP70 0.4 0.64 0 0.8 0 agent PEG S-40 0 0 0.64 0 0
Polysorbate-60 0 0 0 0 0.8 Water gelling Xanthan Gum 0.1 0 0.14 0.2
0.2 agent Methocel ELV15 0.2 0.4 0.32 0.4 0.4 Other Antioxidant
0.02 0.02 0.02 0.02 0.02 Ingredients Preservatives 1 1 1 1 1
Fragrance 0.2 0.2 0.2 0.2 0.2 Foam Specific ND ND ND ND 0.1 gravity
(gr/mL)
[0346] The compositions use only non-ionic solvents, and the total
amount of surface active agent, foam adjuvants and water gelling
agents ranges from 1.4 to 2.1% (w/w). The foam of this example is
useful as a carrier of active pharmaceutical and/or cosmetic active
ingredients, as exemplified in examples below. It is also useful as
lubricating foam, for various purposes.
Example 7
Mixed Oils Foam Carrier Composition
[0347] TABLE-US-00006 Version Version No. 1 No. 2 Ingredient 25%
Oil 12.5% Oil Hydrophobic solvent Mineral oil 11.2% 5.6% Isopropyl
myristate 5.0% 2.5% MCT oil 7.5% 3.8% Foam adjuvant agent Stearyl
Alcohol 0.5% 0.25% Water Water 73.0% 85.2% Surface-active agent
Sucrose ester SP70 0.8% 0.8% Distilled monoglyceride 1.2% 0.6%
Sodium lauryl sulphate 0.1% 0.1% Water gelling agent Xanthan Gum
0.3% 0.3% Methocel ELV15 0.6% 0.6%
[0348] The foams of this example have a non-ionic surfactant to
ionic surfactant ratio (w/w) of 20:1 and 14:1 for versions 1 and 2,
respectively. Total amounts of surface active agent foam adjuvant
and water gelling agent is in the range of 1.75-3.5% (w/w). It is
useful as a carrier of active pharmaceutical and/or cosmetic active
ingredients, as exemplified in examples below. It is also useful as
lubricating foam, for various purposes.
[0349] The following examples, representing optional
drug-containing foams, are prototype formulations, which have not
been optimized for stability and inter-component compatibility.
Such optimization is a customary need, which can be done, using
means, known to those skilled in the art of pharmaceutical
formulation
Example 8
Antibacterial Foam Composition
[0350] TABLE-US-00007 Version 2 Version 3 Version 4 Version 5
Version 1 "Triple "Fucidic "Metro- "Triple Ingredient "Mupirocin"
Antibiotic" Acid" nidazole" Antibiotic" Carrier Ingredients Mineral
oil 48.8% 11.2% 48.8% 5.6% 5.6% Isopropyl myristate 5.0% 2.5% 2.5%
MCT oil 7.5% 3.8% 3.8% Stearyl Alcohol 0.8% 0.5% 0.8% 0.25% 0.25%
Water 50% 73.0% 50% 85.2% 85.2% Sucrose ester SP70 0.8% 0.8% --
0.8% Myrj 40 -- 0.8% -- -- Distilled 1.2% 0.6% 0.6% monoglyceride
Tween 60 0.8% Sodium lauryl 0.05% 0.1% 0.1% sulphate Xanthan Gum
0.2% 0.3% 0.2% 0.3% 0.3% Methocel ELV15 0.2% 0.6% 0.2% 0.6% 0.6%
Active Ingredients Mupirocin 2% Polymyxin B Sulfate 10,000 Units/gr
10,000 Units/gr Bacitracin Zinc 500 Units/gr 500 Units/gr Neomycin
Sulfate* 0.05% 0.05% Pramoxine HCl 1% 1% Fucidic acid 2%
Metronidazole 1%
[0351] The foams of this example contain 100% non-ionic surfactant
or have a non-ionic surfactant to ionic surfactant ratio ranging
from 20:1 to 8:1. Total amounts of surface active agent, foam
adjuvant and water gelling agent ranges from 2.05-3.5% (w/w). It is
useful for the treatment of bacterial skin infection (general),
cellulites, open wounds, cutaneous abscesses, furuncles, insect
bite, impetigo, acne, acne-rosacea, and trichomonas vaginitis.
[0352] In certain embodiments, the foam of this example is useful
for the prevention, decontamination and/or neutralization hazardous
bacterial infestation (such as warfare organisms).
Example 9
Antifungal Foam Composition
[0353] TABLE-US-00008 Version 1 Version 2 Version 3 Version 4
Ingredient "Terbinafine" "Clotrimazole" "Nystatin" "Nystatin"
Carrier Ingredients Mineral oil 48.8% 11.2% 48.8% 5.6% Isopropyl
5.0% 2.5% myristate MCT oil 7.5% 3.8% Stearyl Alcohol 0.8% 0.5%
0.8% 0.25% Water 50% 73.0% 50% 85.2% Sucrose ester 0.8% 0.8% --
0.8% SP70 Myrj 40 -- 0.8% -- Tween 80 0.8% Distilled 1.2% 0.6%
monoglyceride Sodium lauryl 0.05% 0.1% 0.1% sulphate Xanthan Gum
0.2% 0.3% 0.2% 0.3% Methocel 0.2% 0.6% 0.2% 0.6% ELV15 Active
Ingredients Terbinafine 1% clotrimazole 2% Nystatin 100,000 100,000
Units/gr Units/gr
[0354] The foams of this example have 100% non-ionic surfactant or
have a non-ionic surfactant to ionic surfactant ratio ranging from
20:1 to 8:1. Total surface active agent, foaming adjuvant and water
gelling agent ranges from 2.05 to 3.5% (w/w). It is useful in the
treatment of dermatophyte infections, Tinea corporis, Tinea pedis,
Tinea rubrum, Tinea unguium, Tinea cruris, Tinea barbae, and yeast
infections, such as Candidiasis, Tinea versicolor and Candidal
vaginitis.
Example 10
Corticosteroid Foam Composition
[0355] TABLE-US-00009 Version 1 Version 2 Version 3 Ingredient
"Hydrocortisone" "Betamethasone" "Dexamethasone" Carrier
Ingredients Mineral oil 48.8% 11.2% 5.6% Isopropyl 5.0% 2.5%
myristate MCT oil 7.5% 3.8% Stearyl Alcohol 0.8% 0.5% 0.25% Water
50% 73.0% 85.2% Sucrose ester 0.8% 0.4% 0.8% SP70 Tween 80 0.4%
Distilled 1.2% 0.6% monoglyceride Sodium lauryl 0.05% 0.1% sulphate
Xanthan Gum 0.2% 0.3% 0.3% Methocel 0.2% 0.6% 0.6% ELV15 Active
Ingredients Hydrocortisone 1% Betamethasone 0.05% dipropionate
Dexamethasone 0.1% acetate Version 4 Version 5 Ingredient
"Triamcinolone" "Flumetasone" Carrier Ingredients Mineral oil 48.8%
48.8% Stearyl Alcohol 0.8% 0.8% Water 50% 50% Sucrose ester SP70
0.8% 0.8% Sodium lauryl 0.05% 0.05% sulphate Xanthan Gum 0.2% 0.2%
Methocel ELV15 0.2% 0.2% Active Ingredients Triamcinolone 0.1%
acetonide Flumetasone 0.02% pivalate
[0356] The foams of this example have either 100% non-ionic
surfactant or have a non-ionic surfactant to ionic surfactant ratio
ranging from 20:1 to 16:1. Total surface active agent, foaming
adjuvant and water gelling agent ranges from 2.05 to 3.5% (w/w).
Indications include psoriasis, contact dermatitis, atopic
dermatitis, seborrheic dermatitis, nummular dermatitis,
inflammatory acne, chronic dermatitis of the hands and feet,
generalized exfoliative dermatitis, stasis dermatitis, lichen
simplex chronicus, herpes gestationis and pruritic urticarial
papules and plaques of pregnancy.
Example 11
Antiviral Foam Composition
[0357] TABLE-US-00010 Version 1 Version 2 Version 3 Ingredient
"Acyclovir" "Acyclovir" ".alpha.-Interferon" Carrier Ingredients
Mineral oil 48.8% 11.2% 5.6% Isopropyl myristate 5.0% 2.5% MCT oil
7.5% 3.8% Stearyl Alcohol 0.8% 0.5% 0.25% Water 50% 73.0% 85.2%
Sucrose ester SP70 0.8% 0.8% Tween 80 0.8% Distilled monoglyceride
1.2% 0.6% Sodium lauryl sulphate 0.1% Xanthan Gum 0.2% 0.3% 0.3%
Methocel ELV15 0.2% 0.6% 0.6% Active Ingredients Acyclovir 5% 5%
.alpha.-Interferon 105 IU/g
[0358] The foams of this example have either 100% non-ionic
surfactant or have a non-ionic surfactant to ionic surfactant ratio
of 14:1. Total surface active agent, foaming adjuvant and water
gelling agent ranges from 2.05 to 3.5% (w/w). Indications include
Herpes simplex, Herpes zoster, Herpes gestationis and Herpes
simplex genital ulcers.
Example 12
Insect Repellent Foam Composition
[0359] TABLE-US-00011 Ingredient % Isopropyl myristate 2.0% MCT oil
2.0% Stearyl Alcohol 1.2% Water 64.0% Sucrose ester SP70 0.8%
Sodium lauryl sulphate 0.1% Xanthan Gum 0.3% Methocel ELV15 0.6%
Propylene glycol 15% DEET 15%
Example 14
Comparative Tolerability and Acceptability Study of a
Corticosteroid Foam Composition Vs. a Conventional Ointment
[0360] A panel of eight testers was requested to apply about 0.5
gr. of the foam preparation of example 10, Version 2 on one arm and
0.5 gr. of commercial Betamethasone valerate ointment, in a double
blind fashion. They were asked to describe their feeling about the
ease of application, ease of spreading, spreadability and
penetrability of each of the products and to give their general
rating for each of the products on a scale of 0-3 (0=poor; 1=barely
acceptable; 2=acceptable and 3=excellent).
[0361] As demonstrated in the following table, the foam preparation
of example 10, Version 2 obtained higher rates in all aspects of
the test. TABLE-US-00012 Commercial Betamethasone Foam Preparation
Valerate Ointment Property Mean Rating Mean Rating Ease of
application 2.3 1.6 Ease of spreading 2.5 1.9 Spreadability 2.9 1.2
Penetrability 2.0 1.5 Lack of sticky feeling 2.4 1.0 Lack of greasy
feeling 2.2 1.0 Lack of shiny look 1.9 1.4 Overall rating 2.5
1.4
Example 15
Human Safety and Efficacy Study of a Corticosteroid Composition in
Psoriasis Patients
[0362] Two patients with mild to moderate psoriasis were
administered topically a Betamethasone 0.1 2% foam (example 10,
Version 2) twice daily for two weeks.
[0363] Both patients improved significantly, as manifested by
clearance of the psoriatic plaques flattening of the thickened
lesions. FIG. 1 provides an exemplary response to treatment in the
elbows of one of these patients. While betamethasone is know for
its effect in psoriasis, such a beneficial effect after 14 days
treatment is exceptional. The accelerated effect was attributed to
the improved convenience and therefore, improved compliance.
Example 16
Human Safety and Efficacy Study of a Corticosterold Composition in
Psoriasis Patients
[0364] Four patients with moderate to severe, disseminated atopic
dermatitis were administered topically a Betamethasone 0.12% foam
(example 10, Version 2) twice daily for two weeks. All patients
improved significantly, as manifested by complete clearance of all
treated lesions. FIG. 2 provides exemplary responses to treatment
in different body areas, after 10 days of treatment. While
betamethasone is know for its effect in atopic dermatitis, such a
beneficial effect after 10 days treatment is exceptional. The
patients claimed that the use of the foam of the present invention
was significantly more convenient than the corresponding cream and
ointment. Thus, the accelerated effect was attributed to the
improved convenience and therefore, improved compliance.
Example 17
Foam Compositions with Urea
[0365] TABLE-US-00013 EXAMPLE 1 Foam Compositions with Urea
Component % w/w Mineral oil 6.00 6.00 6.00 6.00 Isopropylmeristat
6.00 6.00 6.00 6.00 Glyceryl monostearate 0.50 0.50 0.50 0.50
Stearyl alcohol 0.20 0.20 0.20 1.00 Urea 10.00 10.00 10.00 10.00
Xantan gum 0.30 0.30 0.30 0.30 Methocel K100M 0.30 0.30 0.30 0.30
Myrj 52 3.00 TWEEN 80 1.00 Myrj 49p 3.00 TWEEN 60 1.00 1.00 1.00
Cocamidopropylbetain 0.50 0.50 Phenonip 0.30 0.30 0.30 0.30 Water
to 100.0 to 100.0 to 100.0 to 100.0 Butane/propane 8.00 8.00 18.00
18.00 FoamQuality E E E E Density n/a 0.023 n/a 0.024
Example 18
Compositions with Various Penetration Enhancers
[0366] TABLE-US-00014 Component % w/w Mineral oil 6.00 6.00 6.00
6.00 6.00 Isopropyl myristate 6.00 6.00 6.00 6.00 6.00 Glyceryl
monostearate 0.50 0.50 0.50 0.50 0.50 Stearyl alcohol 1.00 1.00
1.00 1.00 1.00 Xantan gum 0.30 0.30 0.30 0.30 0.30 Methocel K100M
0.30 0.30 0.30 0.30 0.30 TWEEN 60 1.00 TWEEN 80 1.00 1.00 1.00 1.00
MYRJ 49p 3.00 3.00 3.00 3.00 3.00 Propylen glycol 5.00 Glycofurol
1.00 10.00 Urea 10.00 Cocoamidopropyl- 0.50 0.50 0.50 0.50 0.50
bethaine Lidocain base 4.00 4.00 4.00 4.00 4.00 Phenonip 0.30 0.30
0.30 0.30 0.30 Water to 100 to 100 to 100 to 100 to 100
Butane/propane 8 8 8 16 10 Foam Quality E E E E E Density 0.020
0.018 0.019 0.019 0.018 Component % w/w % w/w Isopropyl myristate
30.00 30.00 Glyceryl monostearate 0.50 0.50 Stearic acid 0.45 0.45
Xantan gum 0.30 0.30 Methocel K100M 0.30 0.30 TWEEN 80 1.00 1.00
MYRJ 49p 3.00 3.00 Cocoamidopropylbethaine 0.50 0.50 Transcutol p
20.00 20.00 Hydrophilic drug Effective concentration Hydrophobic
drug Effective concentration Phenonip 0.30 0.30 Water to 100.0 to
100.0 Butane/propane 8.00 8.00 FoamQuality E E Density 0.020
0.020
* * * * *
References